Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									2
	18.2.1.2	Levonorgestrel	Tablet 1.5 mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									26,189.16
			(P,S,T)			Sum of PTR per unit considered for price calculation									176.00
						Number of Packs considered									2
						Average PTR									88.00
						Less: Reduction as per monopoly conditions									22.15
						PTR after reduction									65.85
						Add : 16% Retailer Margin									10.54
		New added medicine in the list of NLEM 2022				Ceiling Price (without GST)									76.38
						% Reduction with compared to Highest Price									25.18%
						Final Ceiling Price (without GST)									76.38
											Minimum Price (Rs.)				88.00
											Maximum Price (Rs.)				88.00
											Average of all considered (Rs.)				88.00
											Ceiling Price (Rs.)				76.38
									TOTAL MAT	**2,62,85,94,709**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1			EZEE (DKT) 1.5 MG TABLET 1	EZEE (DKT)	DKT INDIA LTD	1.5 MG	1	TABLET	8.5	344	0.00%	0.00%	N	8.50	
2			IPILL 1.5 MG TABLET 1	IPILL	PIRAMAL HEALTHCARE LIMITED	1.5 MG	1	TABLET	88	577843464	21.98%	21.98%	Y	88.00	88.00
3			LEEPILL 1.5 MG TABLET 10	LEEPILL	LEEFORD HEALTHCARE	1.5 MG	10	TABLET	13.2	168373	0.01%	0.01%	N	1.32	
4	18.2.1.2	Levonorgestrel	POSTPONE 72 1.5 MG TABLET 1	POSTPONE 72	LEEFORD HEALTHCARE	1.5 MG	1	TABLET	13.2	554797	0.02%	0.02%	N	13.20	
5			STREEPILL 1.5 MG TABLET 1	STREEPILL	HETERO HEALTHCARE LTD	1.5 MG	1	TABLET	88	864952	0.03%	0.03%	N	88.00	
6			T PILL 1.5 MG TABLET 1	T PILL	BESTOCHEM FORMULATIONS (I) LTD	1.5 MG	1	TABLET	56.05	8089811	0.31%	0.31%	N	56.05	
7			UNWANTED 72 1.5 MG TABLET 1	UNWANTED 72	MANKIND PHARMACEUTICALS LTD.	1.5 MG	1	TABLET	88	2041072968	77.65%	77.65%	Y	88.00	88.00
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Ethinylestradiol (A)+Levonorgest	Tablet0.03mg(A)+Tablet0.15mg(B)						87(E) dated 06.01.2023					26.18%
		2	Ormeloxifene(Centchroman)	Tablet30mg						1579(E) dated 31.03.2023					56.00%
		3	IUD containingCopper	As licensed						879(E) dated 24.02.2023					10.07%
		4	Hormone releasingIUD	Contains 52 mg ofLevonorgestrel						879(E) dated 24.02.2023					8.45%
										Average reduction					**25.18%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	7.1.12	Chlorambucil	Tablet 5mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									94.11
			(T)			Sum of PTR per unit considered for price calculation									82.60
						Number of Packs considered									1
						Average PTR									82.60
						Less: Reduction as per monopoly conditions									16.09
						PTR after reduction									66.51
			Current Ceiling Price	**103.25**	**Per Tablet**	Add : 16% Retailer Margin									10.64
			Maximum Permissible PTR	**89**		Ceiling Price (without GST)									77.15
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									19.48%
						Final Ceiling Price (without GST)									77.15
											Minimum Price (Rs.)				82.60
											Maximum Price (Rs.)				82.60
											Average of all considered (Rs.)				82.60
											Ceiling Price (Rs.)				77.15
											Reduction from current ceiling price				25.28%
A. List of items under consideration									TOTAL MAT	**94,10,961**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	7.1.12	Chlorambucil	CELKERAN 5 MG TABLET 30	CELKERAN	CELON LABS	5 MG	30	TABLET	2477.9	9410961	100.00%	100.00%	Y	82.60	82.60
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Temozolomide	Capsule20 mg						5938(E) dated 19.12.2022					11.76%
		2	Lenalidomide	Capsule5mg						5938(E) dated 19.12.2022					10.36%
		3	Temozolomide	Capsule250mg						5938(E) dated 19.12.2022					19.62%
		4	Capecitabine	Tablet500mg						5938(E) dated 19.12.2022					22.71%
		5	L-Asparaginase	Powder for Injection 5000 KU						87(E) dated 06.01.2023					1.93%
		6	Docetaxel	PowderforInjection20mg						87(E) dated 06.01.2023					23.03%
		7	L-Asparaginase	Powderfor Injection10000KU						87(E) dated 06.01.2023					7.92%
		8	Gemcitabine	PowderforInjection1000mg						87(E) dated 06.01.2023					15.33%
		9	Hydroxyurea	Capsule500mg						87(E) dated 06.01.2023					18.10%
		10	Imatinib	Tablet100mg						87(E) dated 06.01.2023					27.62%
		11	Dacarbazine	PowderforInjection200mg						87(E) dated 06.01.2023					16.49%
		12	Gemcitabine	Powder for Injection 200 mg						87(E) dated 06.01.2023					10.89%
		13	Thalidomide	Capsule100mg						87(E) dated 06.01.2023					12.00%
		14	Thalidomide	Capsule50 mg						87(E) dated 06.01.2023					15.35%
		15	Methotrexate	Tablet 2.5mg						87(E) dated 06.01.2023					3.88%
		16	Methotrexate	Tablet 10mg						87(E) dated 06.01.2023					5.24%
		17	Bleomycin	PowderforInjection15units						194(E) dated 11.01.2023					12.02%
		18	Etoposide	Capsule50mg						194(E) dated 11.01.2023					9.84%
		19	Etoposide	Injection20mg/mL						194(E) dated 11.01.2023					7.71%
		20	Docetaxel	PowderforInjection80mg						194(E) dated 11.01.2023					26.68%
		21	Imatinib	Tablet400mg						194(E) dated 11.01.2023					30.26%
		22	Trastuzumab	Injection440mg/50mL						194(E) dated 11.01.2023					22.13%
		23	Bortezomib	Powderfor Injection2mg						194(E) dated 11.01.2023					56.35%
		24	Temozolomide	Capsule100mg						194(E) dated 11.01.2023					32.06%

		25	6-Mercaptopurine	Tablet50mg						194(E) dated 11.01.2023					22.01%
		26	Cyclophosphamide	Powder for Injection 500mg						194(E) dated 11.01.2023					11.72%
		27	Dacarbazine	PowderforInjection500mg						194(E) dated 11.01.2023					19.87%
		28	Cytosinearabinoside	Injection1000mg/vial						194(E) dated 11.01.2023					15.27%
		29	Bendamustine hydrochloride	Injection100 mg/vial						195(E) dated 11.01.2023					43.97%
		30	Lenalidomide	Capsule25 mg						195(E) dated 11.01.2023					17.23%
		31	Oxaliplatin	Injection 5 mg/mL in 10 mL vial						194(E) dated 11.01.2023					25.61%
		32	Vincristine	Injection1mg/mL						484(E) dated 02.02.2023					8..71%
		33	Cytosinearabinoside	Injection500mg/vial						484(E) dated 02.02.2023					9.89%
		34	Cytosinearabinoside	Injection100mg/vial						484(E) dated 02.02.2023					43.57%
		35	Gefitinib	Tablet250mg						484(E) dated 02.02.2023					50.41%
		36	Rituximab	Injection10mg/mL						484(E) dated 02.02.2023					19.33%
		37	Carboplatin	Injection10mg/mL						879(E) dated 24.02.2023					9.50%
		38	Calcium folinate	Tablet 15mg						879(E) dated 24.02.2023					6.37%
		39	Actinomycin D	Powder for Injection 0.5mg						879(E) dated 24.02.2023					1.74%
		40	Cisplatin	Injection1mg/mL						879(E) dated 24.02.2023					17.35%
		41	Ifosfamide	PowderforInjection2000mg						1577(E) dated 31.03.2023					18.26%
		42	Doxorubicin	Injection2mg/mL						1577(E) dated 31.03.2023					23.45%
		43	Cyclophosphamide	Tablet 50mg						1577(E) dated 31.03.2023					11.72%
		44	Imatinib	Capsule 100mg						1577(E) dated 31.03.2023					10.75%
		45	Paclitaxel	Injection100mg/16.7 mL						1577(E) dated 31.03.2023					15.85%
		46	Methotrexate	Tablet 5mg						1577(E) dated 31.03.2023					2.42%
		47	Ifosfamide	Powder for Injection 1000mg						1577(E) dated 31.03.2023					18.26%
		48	Irinotecan HCltrihydrate	Solution for injection 20mg/mL						1579(E) dated 31.03.2023					75.21%
		49	Temozolomide	Tablet 20mg						4886(E) dated 10.11.2023					21.15%
		50	Temozolomide	Tablet 250mg						4886(E) dated 10.11.2023					21.15%
		51	Imatinib	Capsule 400mg						Uploaded in Current Lot					22.88%
										Average reduction					**19.48%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	7.1.5	Arsenic trioxide	Injection 1mg/ml	Per ML		Sum of MAT value considered for price calculation (in Lakhs)									116.92
			(T)			Sum of PTR per unit considered for price calculation									32.67
						Number of Packs considered									1
						Average PTR									32.67
						Less: Reduction as per monopoly conditions									6.37
						PTR after reduction									26.30
			Current Ceiling Price	**67.60**	**Per ML**	Add : 16% Retailer Margin									4.21
			Maximum Permissible PTR	**58.27**		Ceiling Price (without GST)									30.51
			(S.O. 1573(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									19.48%
						Final Ceiling Price (without GST)									30.51
											Minimum Price (Rs.)				32.67
											Maximum Price (Rs.)				32.67
											Average of all considered (Rs.)				32.67
											Ceiling Price (Rs.)				30.51
											Reduction from current ceiling price				54.87%
A. List of items under consideration									TOTAL MAT	**1,16,92,173**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	7.1.5	Arsenic trioxide	ARSENOX 1 MG INJECTION 10 ML	ARSENOX	INTAS PHARMACEUTICALS LTD	1 MG	10	INJECTION	326.67	11692173	100.00%	100.00%	Y	32.67	32.67
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Temozolomide	Capsule20 mg						5938(E) dated 19.12.2022					11.76%
		2	Lenalidomide	Capsule5mg						5938(E) dated 19.12.2022					10.36%
		3	Temozolomide	Capsule250mg						5938(E) dated 19.12.2022					19.62%
		4	Capecitabine	Tablet500mg						5938(E) dated 19.12.2022					22.71%
		5	L-Asparaginase	Powder for Injection 5000 KU						87(E) dated 06.01.2023					1.93%
		6	Docetaxel	PowderforInjection20mg						87(E) dated 06.01.2023					23.03%
		7	L-Asparaginase	Powderfor Injection10000KU						87(E) dated 06.01.2023					7.92%
		8	Gemcitabine	PowderforInjection1000mg						87(E) dated 06.01.2023					15.33%
		9	Hydroxyurea	Capsule500mg						87(E) dated 06.01.2023					18.10%
		10	Imatinib	Tablet100mg						87(E) dated 06.01.2023					27.62%
		11	Dacarbazine	PowderforInjection200mg						87(E) dated 06.01.2023					16.49%
		12	Gemcitabine	Powder for Injection 200 mg						87(E) dated 06.01.2023					10.89%
		13	Thalidomide	Capsule100mg						87(E) dated 06.01.2023					12.00%
		14	Thalidomide	Capsule50 mg						87(E) dated 06.01.2023					15.35%
		15	Methotrexate	Tablet 2.5mg						87(E) dated 06.01.2023					3.88%
		16	Methotrexate	Tablet 10mg						87(E) dated 06.01.2023					5.24%
		17	Bleomycin	PowderforInjection15units						194(E) dated 11.01.2023					12.02%
		18	Etoposide	Capsule50mg						194(E) dated 11.01.2023					9.84%
		19	Etoposide	Injection20mg/mL						194(E) dated 11.01.2023					7.71%
		20	Docetaxel	PowderforInjection80mg						194(E) dated 11.01.2023					26.68%
		21	Imatinib	Tablet400mg						194(E) dated 11.01.2023					30.26%

		22	Trastuzumab	Injection440mg/50mL						194(E) dated 11.01.2023					22.13%
		23	Bortezomib	Powderfor Injection2mg						194(E) dated 11.01.2023					56.35%
		24	Temozolomide	Capsule100mg						194(E) dated 11.01.2023					32.06%
		25	6-Mercaptopurine	Tablet50mg						194(E) dated 11.01.2023					22.01%
		26	Cyclophosphamide	Powder for Injection 500mg						194(E) dated 11.01.2023					11.72%
		27	Dacarbazine	PowderforInjection500mg						194(E) dated 11.01.2023					19.87%
		28	Cytosinearabinoside	Injection1000mg/vial						194(E) dated 11.01.2023					15.27%
		29	Bendamustine hydrochloride	Injection100 mg/vial						195(E) dated 11.01.2023					43.97%
		30	Lenalidomide	Capsule25 mg						195(E) dated 11.01.2023					17.23%
		31	Oxaliplatin	Injection 5 mg/mL in 10 mL vial						194(E) dated 11.01.2023					25.61%
		32	Vincristine	Injection1mg/mL						484(E) dated 02.02.2023					8..71%
		33	Cytosinearabinoside	Injection500mg/vial						484(E) dated 02.02.2023					9.89%
		34	Cytosinearabinoside	Injection100mg/vial						484(E) dated 02.02.2023					43.57%
		35	Gefitinib	Tablet250mg						484(E) dated 02.02.2023					50.41%
		36	Rituximab	Injection10mg/mL						484(E) dated 02.02.2023					19.33%
		37	Carboplatin	Injection10mg/mL						879(E) dated 24.02.2023					9.50%
		38	Calcium folinate	Tablet 15mg						879(E) dated 24.02.2023					6.37%
		39	Actinomycin D	Powder for Injection 0.5mg						879(E) dated 24.02.2023					1.74%
		40	Cisplatin	Injection1mg/mL						879(E) dated 24.02.2023					17.35%
		41	Ifosfamide	PowderforInjection2000mg						1577(E) dated 31.03.2023					18.26%
		42	Doxorubicin	Injection2mg/mL						1577(E) dated 31.03.2023					23.45%
		43	Cyclophosphamide	Tablet 50mg						1577(E) dated 31.03.2023					11.72%
		44	Imatinib	Capsule 100mg						1577(E) dated 31.03.2023					10.75%
		45	Paclitaxel	Injection100mg/16.7 mL						1577(E) dated 31.03.2023					15.85%
		46	Methotrexate	Tablet 5mg						1577(E) dated 31.03.2023					2.42%
		47	Ifosfamide	Powder for Injection 1000mg						1577(E) dated 31.03.2023					18.26%
		48	Irinotecan HCltrihydrate	Solution for injection 20mg/mL						1579(E) dated 31.03.2023					75.21%
		49	Temozolomide	Tablet 20mg						4886(E) dated 10.11.2023					21.15%
		50	Temozolomide	Tablet 250mg						4886(E) dated 10.11.2023					21.15%
		51	Imatinib	Capsule 400mg						Uploaded in Current Lot					22.88%
										Average reduction					**19.48%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									2
	2.2.1	Fentanyl	Injection 50mcg/ML	Per ML		Sum of MAT value considered for price calculation (in Lakhs)									0.17
			(S,T)			Sum of PTR per unit considered for price calculation									36.14
						Number of Packs considered									2
						Average PTR									18.07
			Current Ceiling Price	**28.27**	**Per ML**	Add : 16% Retailer Margin									2.89
			Maximum Permissible PTR	**24.37**		Ceiling Price (without GST)									20.96
			(S.O. 1573(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									0.17%
						Final Ceiling Price (without GST)									20.96
											Minimum Price (Rs.)				18.10
											Maximum Price (Rs.)				18.10
											Average of all considered (Rs.)				18.07
											Ceiling Price (Rs.)				20.96
											Reduction from current ceiling price				25.86%
									TOTAL MAT	**16,925**	100%		M3		
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	2.2.1	Fentanyl	THEMIFENT 50 MCG INJECTION	THEMIFENT	THEMIS MEDICARE LTD.	50 MCG	2	ML	36.08	15839	93.59%	93.59%	Y	18.04	18.04
2			TROFENTYL 50 MCG INJECTION	TROFENTYL	TROIKAA PHARMACEUTICALS LTD	50 MCG	2	ML	36.19	1086	6.41%	6.41%	Y	18.10	18.10

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	6.2.1.4	Benzathine benzylpenicillin	Powder for injection 6 lacs Units (P,S,T)	Each Vial		Sum of MAT value considered for price calculation (in Lakhs)									241.56
						Sum of PTR per unit considered for price calculation									11.51
						Number of Packs considered									1
						Average PTR									11.51
						Less: Reduction as per monopoly conditions									1.43
						PTR after reduction									10.08
			Current Ceiling Price	**15.01**	**Each Pack**	Add : 16% Retailer Margin									1.61
			Maximum Permissible PTR	**12.93**		Ceiling Price (without GST)									11.69
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									12.42%
						Final Ceiling Price (without GST)									11.69
											Minimum Price (Rs.)				11.51
											Maximum Price (Rs.)				11.51
											Average of all considered (Rs.)				11.51
											Ceiling Price (Rs.)				11.69
											Reduction from current ceiling price				22.12%
A. List of items under consideration									TOTAL MAT	**2,41,55,600**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	6.2.1.4	Benzathine benzylpenicillin	PENIDURE LA 600000 IU INJECTION	PENIDURE LA	PFIZER LTD	600000 IU	1	Each Vial	11.51	24155600	100.00%	100.00%	Y	11.51	11.51
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Amoxicillin	Oral liquid 125 mg/5 mL (p)						1579(E) dated 31.03.2023					25.73%
		2	Amoxicillin	Capsule500mg						484(E) dated 02.02.2023					6.09%
		3	Amoxicillin	Capsule250mg						194(E) dated 11.01.2023					4.25%
		4	Amoxicillin	Powder for Injection 500 mg						1578(E) dated 31.03.2023					11.55%
		5	Amoxicillin	Oral liquid 250 mg/5 mL (p)						1577(E) dated 31.03.2023					0.42%
		6	Amoxicillin	Powder for Injection 250 mg						1578(E) dated 31.03.2023					11.55%
		7	Amoxicillin (A) +Clavulanicacid (B)	Tablet 500 mg (A) + 125 mg (B)						87(E) dated 06.01.2023					18.22%
		8	Amoxicillin (A) +Clavulanicacid (B)	Oral liquid 200 mg (A) + 28.5mg(B)/5 mL(p)						484(E) dated 02.02.2023					9.54%
		9	Amoxicillin (A) +Clavulanicacid (B)	Powder for Injection 1 g (A) +200mg (B)						87(E) dated 06.01.2023					7.97%
		10	Amoxicillin (A) +Clavulanicacid (B)	Powderfor Injection500mg(A)+100mg(B)						194(E) dated 11.01.2023					9.55%
		11	Amoxicillin (A) +Clavulanicacid (B)	DrySyrup125mg(A)+31.25(B)/5mL(p)						194(E) dated 11.01.2023					3.48%
		12	Ampicillin	Powder for Injection 500 mg						87(E) dated 06.01.2023					6.16%
		13	Azithromycin	Tablet500mg						484(E) dated 02.02.2023					4.18%
		14	Azithromycin	Capsule 500mg						2124(E) dated 04.05.2023					7.82%
		15	Azithromycin	Oral liquid 200 mg/5 mL (p)						484(E) dated 02.02.2023					10.90%
		16	Azithromycin	Tablet250mg						484(E) dated 02.02.2023					6.54%
		17	Azithromycin	PowderforInjection500mg						194(E) dated 11.01.2023					7.83%
		18	Azithromycin	Capsule250mg						1577(E) dated 31.03.2023					3.09%

		19	Cefadroxil	Tablet500mg					5938(E) dated 19.12.2022				3.86%
		20	Cefadroxil	Oralliquid125mg/5mL(p)					194(E) dated 11.01.2023				6.25%
		21	Cefixime	Tablet200mg					87(E) dated 06.01.2023				11.92%
		22	Cefixime	Oral liquid 50 mg/5 mL (p)					484(E) dated 02.02.2023				10.71%
		23	Cefixime	Oralliquid100mg/5mL(p)					484(E) dated 02.02.2023				3.70%
		24	Cefixime	Tablet400mg					5938(E) dated 19.12.2022				10.57%
		25	Cefixime	Capsule200mg					1577(E) dated 31.03.2023				18.34%
		26	Cefotaxime	PowderforInjection1000mg					87(E) dated 06.01.2023				4.62%
		27	Cefotaxime	Powder for Injection 500 mg					87(E) dated 06.01.2023				4.49%
		28	Cefotaxime	Powder for Injection 250 mg					87(E) dated 06.01.2023				6.13%
		29	Ceftazidime	PowderforInjection1000mg					87(E) dated 06.01.2023				12.88%
		30	Ceftazidime	Powder for Injection 250 mg					484(E) dated 02.02.2023				2.41%
		31	Ceftriaxone	PowderforInjection1000mg					87(E) dated 06.01.2023				7.05%
		32	Ceftriaxone	Powder for Injection 500 mg					87(E) dated 06.01.2023				10.33%
		33	Ceftriaxone	PowderforInjection2000mg					87(E) dated 06.01.2023				6.69%
		34	Ceftriaxone	Powder for Injection 250 mg					87(E) dated 06.01.2023				7.73%
		35	Cefuroxime	Tablet 500 mg					1578(E) dated 31.03.2023				53.28%
		36	Cefuroxime	Injection 1500 mg					1579(E) dated 31.03.2023				26.07%
		37	Cefuroxime	Oralliquid125mg/5mL(p)					5939(E) dated 19.12.2022				25.94%
		38	Ciprofloxacin	Tablet 500mg					87(E) dated 06.01.2023				3.82%
		39	Ciprofloxacin	Tablet 250mg					87(E) dated 06.01.2023				8.31%
		40	Ciprofloxacin	Oral liquid 250mg/5mL(p)					1577(E) dated 31.03.2023				5.70%
		41	Ciprofloxacin	Injection 200mg/100mL					194(E) dated 11.01.2023				4.17%
		42	Clarithromycin	Tablet500mg					5938(E) dated 19.12.2022				31.87%
		43	Clarithromycin	Tablet250mg					5938(E) dated 19.12.2022				27.08%
		44	Clarithromycin	Oralliquid125mg/5mL(p)					194(E) dated 11.01.2023				7.55%
		45	Clindamycin	Injection150mg/mL					1579(E) dated 31.03.2023				38.23%
		46	Co-trimoxazole [Sulphamethoxazole(A) +Trimethoprim(B)]*	Oral liquid 200 mg (A) + 40 mg(B)/5mL(p)					1577(E) dated 31.03.2023				3.57%
		47	Co-trimoxazole [Sulphamethoxazole(A) +Trimethoprim(B)]*	Tablet 400 mg (A) + 80 mg (B)					1577(E) dated 31.03.2023				4.75%
		48	Doxycycline	Power for Injection 100 mg					1579(E) dated 31.03.2023				32.29%
		49	Gentamicin	Injection40mg/mL (2ml)					2124(E) dated 04.05.2023				0.00%
		50	Gentamicin	Injection40mg/mL (1.5 ml)					2124(E) dated 04.05.2023				0.00%
		51	Gentamicin	Injection10mg/mL					879(E) dated 24.02.2023				33.99%
		52	Gentamicin	Injection40mg/mL (more than 20ml)					1577(E) dated 31.03.2023				0.00%
		53	Gentamicin	Injection40mg/mL (3ml-10ml)					1577(E) dated 31.03.2023				29.39%
		54	Gentamicin	Injection40mg/mL (11ml-20ml)					1577(E) dated 31.03.2023				4.80%
		55	Meropenem	Powderfor Injection1000mg (astrihydrate)					1579(E) dated 31.03.2023				66.37%
		56	Meropenem	Powder for Injection 500 mg (astrihydrate)					1579(E) dated 31.03.2023				71.15%
		57	Metronidazole	Tablet400mg					87(E) dated 06.01.2023				3.69%
		58	Metronidazole	Oralliquid200mg/5mL(p)					194(E) dated 11.01.2023				6.98%
		59	Metronidazole	Injection500mg/100mL					194(E) dated 11.01.2023				11.11%
		60	Metronidazole	Tablet200mg					87(E) dated 06.01.2023				3.08%
		61	Metronidazole SF	Injection500mg/100mL					486(E) dated 02.02.2023				11.11%
		62	Nitrofurantoin	Tablet 100 mg					87(E) dated 06.01.2023				9.97%
		63	Nitrofurantoin	Capsule 100 mg					1577(E) dated 31.03.2023				4.79%

		64	Nitrofurantoin	Oral liquid 25mg/5mL(p)						1577(E) dated 31.03.2023				9.97%
		65	Piperacillin (A) +Tazobactam(B)	PowderforInjection4000mg(A)+500mg(B)						87(E) dated 06.01.2023				26.52%
		66	Piperacillin (A) +Tazobactam(B)	PowderforInjection2000mg(A)+250mg(B)						87(E) dated 06.01.2023				20.27%
		67	Piperacillin (A) +Tazobactam(B)	PowderforInjection1000mg(A)+125mg(B)						87(E) dated 06.01.2023				9.41%
		68	Vancomycin	PowderforInjection1000mg						194(E) dated 11.01.2023				20.63%
		69	Vancomycin	Powder for Injection 500 mg						194(E) dated 11.01.2023				9.56%
		70	Vancomycin	Capsule 250mg						1577(E) dated 31.03.2023				12.52%
		71	Vancomycin	Powder for Injection 250 mg						194(E) dated 11.01.2023				7.37%
		72	Clindamycin	Capsule 150mg						5938(E) dated 19.12.2022				9.17%
		73	Clindamycin	Capsule 300mg						5938(E) dated 19.12.2022				3.59%
		74	Co-trimoxazole [Sulphamethoxazole(A) +Trimethoprim(B)]*	Tablet 800mg (A) + 160mg (B)						4886 (E) dated 10.11.2023				1.67%
		75	Doxycycline	Capsule 100mg						484 (E) dated 02.02.2023				1.35%
		76	Doxycycline	Tablet 100mg						1577 (E) dated 31.03.2023				0.00%
										Average reduction				**12.42%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	7.1.1	5-Fluorouracil	Injection 250 mg/5 ml	Per ML		Sum of MAT value considered for price calculation (in Lakhs)									80.47
			(T)			Sum of PTR per unit considered for price calculation									4.37
						Number of Packs considered									2
						Average PTR									2.19
						Less: Reduction as per monopoly conditions									0.43
						PTR after reduction									1.76
			Current Ceiling Price	**2.90**	**Per ML**	Add : 16% Retailer Margin									0.28
			Maximum Permissible PTR	**2.50**		Ceiling Price (without GST)									2.04
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									23.84%
						Final Ceiling Price (without GST)									2.04
											Minimum Price (Rs.)				2.06
											Maximum Price (Rs.)				2.31
											Average of all considered (Rs.)				2.19
											Ceiling Price (Rs.)				2.04
											Reduction from current ceiling price				29.66%
									TOTAL MAT	**80,64,336**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1			5 FLUCEL 250 MG INJECTION 5 ML	5 FLUCEL	CELON LABS	250 MG	5	INJECTION	10.28	1054253	13.07%	99.78%	Y	2.06	2.06
2	7.1.1	5-Fluorouracil	5 FLUCEL 500 MG INJECTION 10 ML	5 FLUCEL	CELON LABS	500 MG	10	INJECTION	23.05	6992442	86.71%	99.78%	Y	2.31	2.31
3			5FU CBC 250 MG INJECTION 5 ML	5FU CBC	CHANDRA BHAGAT PHARMA PVT. LT	250 MG	5	INJECTION	19.05	17640	0.22%	0.22%	N	3.81	

B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Temozolomide	Capsule20 mg						5938(E) dated 19.12.2022					11.76%
		2	Lenalidomide	Capsule5mg						5938(E) dated 19.12.2022					10.36%
		3	Temozolomide	Capsule250mg						5938(E) dated 19.12.2022					19.62%
		4	Capecitabine	Tablet500mg						5938(E) dated 19.12.2022					22.71%
		5	L-Asparaginase	Powder for Injection 5000 KU						87(E) dated 06.01.2023					1.93%
		6	Docetaxel	PowderforInjection20mg						87(E) dated 06.01.2023					23.03%
		7	L-Asparaginase	Powderfor Injection10000KU						87(E) dated 06.01.2023					7.92%
		8	Gemcitabine	PowderforInjection1000mg						87(E) dated 06.01.2023					15.33%
		9	Hydroxyurea	Capsule500mg						87(E) dated 06.01.2023					18.10%
		10	Imatinib	Tablet100mg						87(E) dated 06.01.2023					27.62%
		11	Dacarbazine	PowderforInjection200mg						87(E) dated 06.01.2023					16.49%
		12	Gemcitabine	Powder for Injection 200 mg						87(E) dated 06.01.2023					10.89%
		13	Thalidomide	Capsule100mg						87(E) dated 06.01.2023					12.00%
		14	Thalidomide	Capsule50 mg						87(E) dated 06.01.2023					15.35%
		15	Methotrexate	Tablet 2.5mg						87(E) dated 06.01.2023					3.88%
		16	Methotrexate	Tablet 10mg						87(E) dated 06.01.2023					5.24%
		17	Bleomycin	PowderforInjection15units						194(E) dated 11.01.2023					12.02%
		18	Etoposide	Capsule50mg						194(E) dated 11.01.2023					9.84%
		19	Etoposide	Injection20mg/mL						194(E) dated 11.01.2023					7.71%
		20	Docetaxel	PowderforInjection80mg						194(E) dated 11.01.2023					26.68%
		21	Imatinib	Tablet400mg						194(E) dated 11.01.2023					30.26%

		22	Trastuzumab	Injection440mg/50mL					194(E) dated 11.01.2023					22.13%
		23	Bortezomib	Powderfor Injection2mg					194(E) dated 11.01.2023					56.35%
		24	Temozolomide	Capsule100mg					194(E) dated 11.01.2023					32.06%
		25	6-Mercaptopurine	Tablet50mg					194(E) dated 11.01.2023					22.01%
		26	Cyclophosphamide	Powder for Injection 500mg					194(E) dated 11.01.2023					11.72%
		27	Dacarbazine	PowderforInjection500mg					194(E) dated 11.01.2023					19.87%
		28	Cytosinearabinoside	Injection1000mg/vial					194(E) dated 11.01.2023					15.27%
		29	Bendamustine hydrochloride	Injection100 mg/vial					195(E) dated 11.01.2023					43.97%
		30	Lenalidomide	Capsule25 mg					195(E) dated 11.01.2023					17.23%
		31	Oxaliplatin	Injection 5 mg/mL in 10 mL vial					194(E) dated 11.01.2023					25.61%
		32	Vincristine	Injection1mg/mL					484(E) dated 02.02.2023					8..71%
		33	Cytosinearabinoside	Injection500mg/vial					484(E) dated 02.02.2023					9.89%
		34	Cytosinearabinoside	Injection100mg/vial					484(E) dated 02.02.2023					43.57%
		35	Gefitinib	Tablet250mg					484(E) dated 02.02.2023					50.41%
		36	Rituximab	Injection10mg/mL					484(E) dated 02.02.2023					19.33%
		37	Carboplatin	Injection10mg/mL					879(E) dated 24.02.2023					9.50%
		38	Calcium folinate	Tablet 15mg					879(E) dated 24.02.2023					6.37%
		39	Actinomycin D	Powder for Injection 0.5mg					879(E) dated 24.02.2023					1.74%
		40	Cisplatin	Injection1mg/mL					879(E) dated 24.02.2023					17.35%
		41	Ifosfamide	PowderforInjection2000mg					1577(E) dated 31.03.2023					18.26%
		42	Doxorubicin	Injection2mg/mL					1577(E) dated 31.03.2023					23.45%
		43	Cyclophosphamide	Tablet 50mg					1577(E) dated 31.03.2023					11.72%
		44	Imatinib	Capsule 100mg					1577(E) dated 31.03.2023					10.75%
		45	Paclitaxel	Injection100mg/16.7 mL/30mg/5ml					1577(E) dated 31.03.2023					15.85%
		46	Methotrexate	Tablet 5mg					1577(E) dated 31.03.2023					2.42%
		47	Ifosfamide	Powder for Injection 1000mg					1577(E) dated 31.03.2023					18.26%
		48	Irinotecan HCltrihydrate	Solution for injection 20mg/mL					1579(E) dated 31.03.2023					75.21%
		49	Temozolomide	Tablet 20mg					4886(E) dated 10.11.2023					21.15%
		50	Temozolomide	Tablet 250mg					4886(E) dated 10.11.2023					21.15%
		51	Imatinib	Capsule 400mg					Uploaded in Current Lot					22.88%
									Average reduction					**19.48%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									0
	17.4.2	Hyoscine Butyl Bromide	Injection 20 mg/ ml	Per ML		Sum of MAT value considered for price calculation (in Lakhs)									3,043.84
			(T)			Sum of PTR per unit considered for price calculation									10.84
						Number of Packs considered									1
						Average PTR									10.84
						Less: Reduction as per monopoly conditions									1.15
						PTR after reduction									9.69
			Current Ceiling Price	**12.99**	**Per ML**	Add : 16% Retailer Margin									1.55
			Maximum Permissible PTR	**11.19**		Ceiling Price (without GST)									11.24
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									10.64%
						Final Ceiling Price (without GST)									11.24
											Minimum Price (Rs.)				10.84
											Maximum Price (Rs.)				10.84
											Average of all considered (Rs.)				10.84
											Ceiling Price (Rs.)				11.24
											Reduction from current ceiling price				13.47%
									TOTAL MAT	**30,44,17,981**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	17.4.2	Hyoscine butylbromide	BISCOTAS 20 MG INJECTION 1 MI	BISCOTAS	INTAS PHARMACEUTICALS LTD	20 MG	1	ML	4.88	161	0.00%	0.00%	N	4.88	
			BUSCOGAST 20 MG INJECTION 1	BUSCOGAST	SANOFI INDIA LTD.	20 MG	1	ML	10.84	304384303	99.99%	99.99%	Y	10.84	10.84
2			HYOKEM 20 MG INJECTION 1 ML	HYOKEM	ALKEM LABORATORIES LTD.	20 MG	1	ML	8.79	33516	0.01%	0.01%	N	8.79	
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Dicyclomine	Injection 10 mg/mL	Per ML (Less than 10ml pack)					1577(E) dt 31.03.2023					9.89%
		2	Dicyclomine	Injection 10 mg/mL	Per ML (10ml pack or more pack)					1577(E) dt 31.03.2023					11.38%
										Average reduction					**10.64%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	17.1.1	Omeprazole	Capsule 40mg	Per Capsule		Sum of MAT value considered for price calculation (in Lakhs)									0.20
			(P,S,T)			Sum of PTR per unit considered for price calculation									5.29
						Number of Packs considered									1
						Average PTR									5.29
			Current Ceiling Price	**6.14**	**Per Capsule**	Less: Reduction as per monopoly conditions									0.40
			Maximum Permissible PTR	**5.29**		PTR after reduction									4.89
			(S.O. 1573(E) dated 31.03.2023)			Add : 16% Retailer Margin									0.78
						Ceiling Price (without GST)									5.67
						% Reduction with compared to Highest Price									7.54%
						Final Ceiling Price (without GST)									5.67
											Minimum Price (Rs.)				5.29
											Maximum Price (Rs.)				5.29
											Average of all considered (Rs.)				5.29
											Ceiling Price (Rs.)				5.67
											Reduction from current ceiling price				7.65%
									TOTAL MAT	**20,074**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	17.1.1	Omeprazole	OMCAR 40 MG CAPSULE 10	OMCAR	TARGOF PURE DRUGS TD.	40 MG	10	CAPSULE	69.22	20074	100.00%	100.00%	Y	6.92	5.29
	Note: The PTR of item at S.N. 1 Is higher than the Maximum Permissible PTR, therefore restricted to Maximum Permissible PTR.														
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Omeprazole	Capsule 20 mg						484(E) dated 02.02.2023					0.23%
		2	Omeprazole	Powder for oral liquid 20mg						1577(E) dated 31.03.2023					0.85%
		3	Omeprazole	Tablet 20 mg						1577(E) dated 31.03.2023					23.97%
		4	Omeprazole	Tablet 40 mg						1577(E) dated 31.03.2023					12.10%
		5	Omeprazole	Capsule 10 mg						1577(E) dated 31.03.2023					0.54%
										Average reduction					**7.54%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	26.4	Cholecalciferol	Solid oral dosage form 1000 IU	Per GM		Sum of MAT value considered for price calculation (in Lakhs)									17.04
			Sachet/Granuels/Powder			Sum of PTR per unit considered for price calculation									23.75
			(P,S,T)			Number of Packs considered									1
						Average PTR									23.75
						Less: Reduction as per monopoly conditions									3.80
			New Added in NLEM 2022			PTR after reduction									19.95
						Add : 16% Retailer Margin									3.19
						Ceiling Price (without GST)									23.14
						% Reduction with compared to Highest Price									15.99%
						Final Ceiling Price (without GST)									23.14
											Minimum Price (Rs.)				23.75
											Maximum Price (Rs.)				23.75
											Average of all considered (Rs.)				23.75
											Ceiling Price (Rs.)				23.14
A. List of items under consideration									TOTAL MAT	**17,03,985**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	26.4	VITAMIN D3 (CHOI	OB CAL 3 1000 IU GRANULES 1 GM	OB CAL 3	OBSURGE BIOTECH LTD	1000 IU	1	GRANULES	23.75	1703985	100.00%	100.00%	Y	23.75	23.75

B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Cholecalciferol	Solid oral dosage form 1000 IU Tablet						5938(E) dated 19.12.2022					7.87%
		2	Cholecalciferol	Oralliquid400 IU/mL						194(E) dated 11.01.2023					10.18%
		3	Cholecalciferol	Solid oral dosage form 60000 IU Tablets						484(E) dated 02.02.2023					21.73%
		4	Cholecalciferol	Solid oral dosage form 60000 IU Capsule						1577(E) dated 31.03.2023					9.80%
		5	Cholecalciferol	Solid oral dosage form 1000 IU Capsule						1577(E) dated 31.03.2023					11.23%
		6	Cholecalciferol	Solid oral dosage form 60000 IU Sachet/Granuels/Powder						1578(E) dated 31.03.2023					35.15%
										Average reduction					**15.99%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									4
	24.1.2	Budesonide (A) + Formoterol (B)	Inhalation 100mcg (A) + 6mcg (B)	Per Metered dose		Sum of MAT value considered for price calculation (in Lakhs)									1,718.72
		MDI	(P,S,T)			Sum of PTR per unit considered for price calculation									10.25
						Number of Packs considered									6
						Average PTR									1.71
			Current Ceiling Price	**2.34**	**Per Metered dose**	Add : 16% Retailer Margin									0.27
			Maximum Permissible PTR	**2.01**		Ceiling Price (without GST)									1.98
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									8.65%
						Final Ceiling Price (without GST)									1.98
											Minimum Price (Rs.)				1.12
											Maximum Price (Rs.)				1.87
											Average of all considered (Rs.)				1.71
											Ceiling Price (Rs.)				1.98
											Reduction from current ceiling price				15.38%
A. List of items under consideration									TOTAL MAT	**17,18,72,115**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.2	Budesonide (A) + Formoterol (B)	BUDAMATE 100 MCG INHALER 120 MDI	BUDAMATE	LUPIN LTD	6/100 MCG	120	Per MDI	223.5	387951	0.23%	17.17%	Y	1.86	1.86
2	24.1.2		BUDAMATE HFA 6/100 MCG TRANSHALER 20	BUDAMATE	LUPIN LTD	6/100 MCG	200	Per MDI	223.5	29111407	16.94%	17.17%	Y	1.12	1.12
3	24.1.2		BUDETROL 6/100 MCG INHALER 120 MDI	BUDETROL	MACLEODS PHARMACEUTICALS PVT.	6/100 MCG	120	Per MDI	199.7	7803687	4.54%	4.54%	Y	1.66	1.66
4	24.1.2		FORACORT CFC FREE 6/100 MCG INHALER 12	FORACORT	CIPLA LTD.	6/100 MCG	120	Per MDI	224.64	94915359	55.22%	56.66%	Y	1.87	1.87
5	24.1.2		FORACORT NEOHALER 6/100 MCG INHALER	FORACORT	CIPLA LTD.	6/100 MCG	120	Per MDI	224.64	2479971	1.44%	56.66%	Y	1.87	1.87
6	24.1.2		FORMONIDE HFA 6/100 MCG INHALER 120 M	FORMONIDE	ZYDUS CADILA - ZHL	6/100 MCG	120	Per MDI	224.64	37173739	21.63%	21.63%	Y	1.87	1.87

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									4
	24.1.2	Budesonide (A) + Formoterol (B)	Inhalation 100mcg (A) + 6mcg (B)	Per dose		Sum of MAT value considered for price calculation (in Lakhs)									1,547.00
		DPI	(P,S,T)			Sum of PTR per unit considered for price calculation									14.91
						Number of Packs considered									4
						Average PTR									3.73
			Current Ceiling Price	**4.72**	**Per dose**	Add : 16% Retailer Margin									0.60
			Maximum Permissible PTR	**4.06**		Ceiling Price (without GST)									4.32
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									1.39%
						Final Ceiling Price (without GST)									4.32
											Minimum Price (Rs.)				3.57
											Maximum Price (Rs.)				3.78
											Average of all considered (Rs.)				3.73
											Ceiling Price (Rs.)				4.32
											Reduction from current ceiling price				8.47%
A. List of items under consideration									TOTAL MAT	**15,52,41,207**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.2	Budesonide (A) + Formoterol (B)	AIRTEC FB DPI 6/100 MCG CAPSULE 30	AIRTEC FB	GLENMARK PHARMACEUTICALS LTD.	6/100 MCG	30	CAPSULE	91.2	520387	0.34%	0.34%	N	3.04	
2	24.1.2		BUDAMATE 6/100 MCG RESPICAP 30	BUDAMATE	LUPIN LTD	6/100 MCG	30	RESPICAP	113.25	27602558	17.78%	17.78%	Y	3.78	3.78
3	24.1.2		BUDETROL 6/100 MCG CAPSULE 30	BUDETROL	MACLEODS PHARMACEUTICALS PVT.	6/100 MCG	30	CAPSULE	107.21	8740145	5.63%	5.63%	Y	3.57	3.57
4	24.1.2		FORACORT 6/100 MCG ROTACAP 30	FORACORT	CIPLA LTD.	6/100 MCG	30	ROTACAP	113.28	88979900	57.32%	57.32%	Y	3.78	3.78
5	24.1.2		FORMONIDE 6/100 MCG RESPICAP 30	FORMONIDE	ZYDUS CADILA - ZHL	6/100 MCG	30	RESPICAP	113.25	29377562	18.92%	18.92%	Y	3.78	3.78
6	24.1.2		QUIKHALE FB 6/100 MCG ROTACAP 40	QUIKHALE FB	INTAS PHARMACEUTICALS LTD	6/100 MCG	40	ROTACAP	85	20655	0.01%	0.01%	N	2.13	

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									7
	24.1.2	Budesonide (A) + Formoterol (B)	Inhalation 200mcg (A) + 6mcg (B)	Per Metered dose		Sum of MAT value considered for price calculation (in Lakhs)									19,719.05
		MDI	(P,S,T)			Sum of PTR per unit considered for price calculation									27.22
						Number of Packs considered									11
						Average PTR									2.47
			Current Ceiling Price	**3.33**	**Per Metered dose**	Add : 16% Retailer Margin									0.40
			Maximum Permissible PTR	**2.87**		Ceiling Price (without GST)									2.87
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									13.78%
						Final Ceiling Price (without GST)									2.87
											Minimum Price (Rs.)				1.60
											Maximum Price (Rs.)				2.87
											Average of all considered (Rs.)				2.47
											Ceiling Price (Rs.)				2.87
											Reduction from current ceiling price				13.81%
A. List of items under consideration									TOTAL MAT	**1,99,58,90,316**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.2	Budesonide (A) + Formoterol (B)	AIRTEC FB 6/200 MCG INHALER 150 MDI	AIRTEC FB	GLENMARK PHARMACEUTICALS LTD.	6/200 MCG	150	Per MDI	134.16	119000	0.01%	0.01%	N	0.89	
2	24.1.2		BUDAMATE 200 MCG INHALER 120 MDI	BUDAMATE	LUPIN LTD	6/200 MCG	120	Per MDI	281.39	4746469	0.24%	19.16%	Y	2.34	2.34
3	24.1.2		BUDAMATE HFA 6/200 MCG TRANSHALER 1	BUDAMATE	LUPIN LTD	6/200 MCG	120	Per MDI	281.39	377662683	18.92%	19.16%	Y	2.34	2.34
4	24.1.2		BUDETROL 6/200 MCG INHALER 120 MDI	BUDETROL	MACLEODS PHARMACEUTICALS PVT.	6/200 MCG	120	Per MDI	281.83	99126733	4.97%	4.97%	Y	2.35	2.35
5	24.1.2		COMBIHALE FB 6/200 MCG INHALER 120 MD	COMBIHALE FB	MANKIND PHARMACEUTICALS LTD.	6/200 MCG	120	Per MDI	284.74	37412922	1.87%	1.87%	Y	2.37	2.37
6	24.1.2		DIGIHALER FB 6/200 MCG INHALER 120 MDI	DIGIHALER FB	GLENMARK PHARMACEUTICALS LTD.	6/200 MCG	120	Per MDI	324.79	80133163	4.01%	4.01%	Y	2.71	2.71
7	24.1.2		FOMTIDE 6/200 MCG INHALER 120 MDI	FOMTIDE	SUN PHARMA LABORATORIES LTD.	6/200 MCG	120	Per MDI	319.38	24756515	1.24%	1.24%	Y	2.66	2.66
8	24.1.2		FOMTIDE CFC FREE 6/200 MCG INHALER 9.2	FOMTIDE	SUN PHARMA LABORATORIES LTD.	6/200 MCG	120	Per MDI	208.12	48076	0.00%	0.00%	N	1.73	
9	24.1.2		FORACORT 6/200 MCG MULTIHALER 120 MD	FORACORT	CIPLA LTD.	6/200 MCG	120	Per MDI	319.67	72665172	3.64%	59.06%	Y	2.66	2.66
10	24.1.2		FORACORT 6/200 MCG MULTIHALER 300 MD	FORACORT	CIPLA LTD.	6/200 MCG	300	Per MDI	692.09	692	0.00%	0.00%	N	2.31	
11	24.1.2		FORACORT CFC 6/200 MCG INHALER 200 MD	FORACORT	CIPLA LTD.	6/200 MCG	200	Per MDI	319.67	891552588	44.67%	59.06%	Y	1.60	1.60
12	24.1.2		FORACORT NEOHALER 6/200 MCG INHALER	FORACORT	CIPLA LTD.	6/200 MCG	120	Per MDI	319.67	33369454	1.67%	59.06%	Y	2.66	2.66
13	24.1.2		FORACORT SYNCHROBREATHE 6/200 MCG I	FORACORT	CIPLA LTD.	6/200 MCG	120	Per MDI	385.91	181273419	9.08%	59.06%	Y	3.22	2.87
14	24.1.2		FORMONIDE HFA 6/200 MCG INHALER 120 M	FORMONIDE	ZYDUS CADILA - ZHL	6/200 MCG	120	Per MDI	319.11	169206124	8.48%	8.48%	Y	2.66	2.66
15	24.1.2		PULMOSMART 200 MG INHALER 120 MD	PULMOSMART	ALKEM LABORATORIES LTD.	6/200 MCG	120	Per MDI	257.14	11257332	0.56%	0.56%	N	2.14	
16	24.1.2		QUIKHALE FB 6/200 MCG INHALER 120 MDI	QUIKHALE FB	INTAS PHARMACEUTICALS LTD	6/200 MCG	120	Per MDI	319.68	12559974	0.63%	0.63%	N	2.66	

Note: The PTR of item at S.N. 13 is higher than the Maximum Permissible PTR, therefore restricted to Maximum Permissible PTR.

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									7
	24.1.2	Budesonide (A) + Formoterol (B)	Inhalation 200mcg (A) + 6mcg (B)	Per dose		Sum of MAT value considered for price calculation (in Lakhs)									20,586.62
		DPI	(P,S,T)			Sum of PTR per unit considered for price calculation									33.98
						Number of Packs considered									7
						Average PTR									4.85
			Current Ceiling Price	**6.27**	**Per dose**	Add : 16% Retailer Margin									0.78
			Maximum Permissible PTR	**5.40**		Ceiling Price (without GST)									5.63
			(S.O. 1573(E) dated 31.03.2023 and S.O 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									3.11%
						Final Ceiling Price (without GST)									5.63
											Minimum Price (Rs.)				4.46
											Maximum Price (Rs.)				5.01
											Average of all considered (Rs.)				4.85
											Ceiling Price (Rs.)				5.63
											Reduction from current ceiling price				10.21%
A. List of items under consideration									TOTAL MAT	**2,09,89,50,567**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.2	Budesonide (A) + Formoterol (B)	AIRTEC FB DPI 6/200 MCG CAPSULE 30	AIRTEC FB	GLENMARK PHARMACEUTICALS LTD.	6/200 MCG	30	CAPSULE	134.16	40782091	1.94%	1.94%	Y	4.47	4.47
2	24.1.2		BUDAMATE 6/200 MCG RESPICAP 30	BUDAMATE	LUPIN LTD	6/200 MCG	30	RESPICAP	150.21	463641717	22.09%	22.09%	Y	5.01	5.01
3	24.1.2		BUDETROL 6/200 MCG CAPSULE 30	BUDETROL	MACLEODS PHARMACEUTICALS PVT.	6/200 MCG	30	CAPSULE	150.23	209602952	9.99%	9.99%	Y	5.01	5.01
4	24.1.2		BUDEVIN F 6/200 MCG CAPSULE 30	BUDEVIN F	DIVINE LIFECARE PVT LTD	6/200 MCG	30	CAPSULE	130.54	1423	0.00%	0.00%	N	4.35	
5	24.1.2		COMBIHALE FB 6/200 MCG REDICAPS 30	COMBIHALE FB	MANKIND PHARMACEUTICALS LTD.	6/200 MCG	30	REDICAPS	133.91	49602540	2.36%	2.36%	Y	4.46	4.46
6	24.1.2		FOMTIDE 6/200 MCG OCTACAP 30	FOMTIDE	SUN PHARMA LABORATORIES LTD.	6/200 MCG	30	OCTACAP	150.23	29139213	1.39%	1.39%	Y	5.01	5.01
7	24.1.2		FORACORT 6/200 MCG ROTACAP 30	FORACORT	CIPLA LTD.	6/200 MCG	30	ROTACAP	150.24	1108216944	52.80%	52.80%	Y	5.01	5.01
8	24.1.2		FORMONIDE 6/200 MCG RESPICAP 30	FORMONIDE	ZYDUS CADILA - ZHL	6/200 MCG	30	RESPICAP	150.24	157676623	7.51%	7.51%	Y	5.01	5.01
9	24.1.2		PULMOSMART 200 6/200 MCG CAPSULE 30	PULMOSMART	ALKEM LABORATORIES LTD.	6/200 MCG	30	CAPSULE	120.71	19447226	0.93%	0.93%	N	4.02	
10	24.1.2		QUIKHALE FB 6/200 MCG ROTACAP 40	QUIKHALE FB	INTAS PHARMACEUTICALS LTD	6/200 MCG	40	ROTACAP	150.24	20834779	0.99%	0.99%	N	3.76	
11	24.1.2		SYMBIVA 6/200 MCG OCTACAP 30	SYMBIVA	SUN PHARMA LABORATORIES LTD.	6/200 MCG	30	OCTACAP	120.46	5059	0.00%	0.00%	N	4.02	

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									7
	24.1.2	Budesonide (A) + Formoterol (B)	Inhalation 400mcg (A) + 6mcg (B)	Per Metered dose		Sum of MAT value considered for price calculation (in Lakhs)									11,296.26
		MDI	(P,S,T)			Sum of PTR per unit considered for price calculation									25.92
						Number of Packs considered									10
						Average PTR									2.59
			Current Ceiling Price	**3.80**	**Per Metered dose**	Add : 16% Retailer Margin									0.41
			Maximum Permissible PTR	**3.27**		Ceiling Price (without GST)									3.01
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									19.25%
						Final Ceiling Price (without GST)									3.01
											Minimum Price (Rs.)				0.19
											Maximum Price (Rs.)				3.21
											Average of all considered (Rs.)				2.59
											Ceiling Price (Rs.)				3.01
											Reduction from current ceiling price				20.79%
A. List of items under consideration									TOTAL MAT	**1,13,55,83,787**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.2		BUDAMATE 400 MCG INHALER 120 MDI	BUDAMATE	LUPIN LTD	6/400 MCG	120	Per MDI	352.36	3602838	0.32%	21.09%	Y	2.94	2.94
2	24.1.2		BUDAMATE HFA 6/400 MCG TRANSHALER 12	BUDAMATE	LUPIN LTD	6/400 MCG	120	Per MDI	352.36	235815468	20.77%	21.09%	Y	2.94	2.94
3	24.1.2		BUDETROL 134 A 6/400 MCG INHALER 1	BUDETROL	MACLEODS PHARMACEUTICALS PVT.	6/400 MCG	120	Per MDI	352.97	26473	0.00%	0.00%	N	2.94	
4	24.1.2		BUDETROL 6/400 MCG INHALER 120 MDI	BUDETROL	MACLEODS PHARMACEUTICALS PVT.	6/400 MCG	120	Per MDI	352.97	61174630	5.39%	5.39%	Y	2.94	2.94
5	24.1.2		COMBIHALE FB 6/400 MCG INHALER 120 MD	COMBIHALE FB	MANKIND PHARMACEUTICALS LTD.	6/400 MCG	120	Per MDI	314.29	14649057	1.29%	1.31%	Y	2.62	2.62
6	24.1.2		COMBIHALE FB 6/400 MCG INHALER 400 DP	COMBIHALE FB	MANKIND PHARMACEUTICALS LTD.	6/400 MCG	400	Per MDI	77.86	213347	0.02%	1.31%	Y	0.19	0.19
7	24.1.2	Budesonide (A) + Formoterol (B)	DIGIHALER FB 6/400 MCG INHALER 120 MD	DIGIHALER FB	GLENMARK PHARMACEUTICALS LTD.	6/400 MCG	120	Per MDI	365.21	51095801	4.50%	4.50%	Y	3.04	3.04
8	24.1.2		FOMTIDE NF 6/400 MCG INHALER 1	FOMTIDE NF	SUN PHARMA LABORATORIES LTD.	6/400 MCG	120	Per MDI	323.93	14253	0.00%	0.00%	N	2.70	
9	24.1.2		FORACORT 6/400 MCG INHALER 120 MDI	FORACORT	CIPLA LTD.	6/400 MCG	120	Per MDI	364.8	526263996	46.34%	54.92%	Y	3.04	3.04
10	24.1.2		FORACORT SYNCHROBREATHE 6/400 MCG IN	FORACORT	CIPLA LTD.	6/400 MCG	120	Per MDI	384.96	97387566	8.58%	54.92%	Y	3.21	3.21
11	24.1.2		FORMONIDE HFA 6/400 MCG INHALER 120 M	FORMONIDE	ZYDUS CADILA - ZHL	6/400 MCG	120	Per MDI	363.89	115410909	10.16%	10.16%	Y	3.03	3.03
12	24.1.2		PULMOSMART 400 MG INHALER 120 MD	PULMOSMART	ALKEM LABORATORIES LTD.	6/400 MCG	120	Per MDI	293.57	5916903	0.52%	0.52%	N	2.45	
13	24.1.2		QUIKHALE FB 6/400 MCG INHALER 160 MDI	QUIKHALE FB	INTAS PHARMACEUTICALS LTD	6/400 MCG	160	Per MDI	314.81	24012548	2.11%	2.11%	Y	1.97	1.97

Note: Strengths of item no. 1 & 12 and pack sizes of item nos. 3 & 8 are confirmed through websources

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									8
	24.1.2	Budesonide (A) + Formoterol (B)	Inhalation 400mcg (A) + 6mcg (B)	Per dose		Sum of MAT value considered for price calculation (in Lakhs)									18,763.88
		DPI	(P,S,T)			Sum of PTR per unit considered for price calculation									48.77
						Number of Packs considered									8
						Average PTR									6.10
			Current Ceiling Price	**8.01**	**Per dose**	Add : 16% Retailer Margin									0.98
			Maximum Permissible PTR	**6.90**		Ceiling Price (without GST)									7.07
			(S.O. 1573(E) dated 31.03.2023 and S.O 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									4.75%
						Final Ceiling Price (without GST)									7.07
											Minimum Price (Rs.)				4.76
											Maximum Price (Rs.)				6.40
											Average of all considered (Rs.)				6.10
											Ceiling Price (Rs.)				7.07
											Reduction from current ceiling price				11.74%
A. List of items under consideration									TOTAL MAT	**1,89,37,29,164**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.2	Budesonide (A) + Formoterol (B)	AIRTEC FB DPI 6/400 MCG CAPSULE 30	AIRTEC FB	GLENMARK PHARMACEUTICALS LTD.	6/400 MCG	30	CAPSULE	192	60759478	3.21%	3.21%	Y	6.40	6.40
2	24.1.2		BUDAMATE 6/400 MCG RESPICAP 30	BUDAMATE	LUPIN LTD	6/400 MCG	30	RESPICAP	192	508503417	26.85%	26.85%	Y	6.40	6.40
3	24.1.2		BUDETROL 6/400 MCG CAPSULE 30	BUDETROL	MACLEODS PHARMACEUTICALS PVT.	6/400 MCG	30	CAPSULE	192	202262889	10.68%	10.68%	Y	6.40	6.40
4	24.1.2		BUDEVIN F 6/400 MCG CAPSULE 30	BUDEVIN F	DIVINE LIFECARE PVT LTD	6/400 MCG	30	CAPSULE	166.43	35450	0.00%	0.00%	N	5.55	
5	24.1.2		COMBIHALE FB 6/400 MCG REDICAPS 30	COMBIHALE FB	MANKIND PHARMACEUTICALS LTD.	6/400 MCG	30	REDICAPS	168.21	44122156	2.33%	2.33%	Y	5.61	5.61
6	24.1.2		FOMTIDE 6/400 MCG OCTACAP 30	FOMTIDE	SUN PHARMA LABORATORIES LTD.	6/400 MCG	30	OCTACAP	192	28606093	1.51%	1.51%	Y	6.40	6.40
7	24.1.2		FORACORT 6/400 MCG ROTACAP 30	FORACORT	CIPLA LTD.	6/400 MCG	30	ROTACAP	192	867407811	45.80%	45.80%	Y	6.40	6.40
8	24.1.2		FORMONIDE 6/400 MCG RESPICAP 30	FORMONIDE	ZYDUS CADILA - ZHL	6/400 MCG	30	RESPICAP	192	143614118	7.58%	7.58%	Y	6.40	6.40
9	24.1.2		IBINIDE 6/400 MCG NEXCAP 30	IBINIDE	INDIABULLS PHARMACEUTICALS LTD	6/400 MCG	30	NEXCAP	144.96	290	0.00%	0.00%	N	4.83	
10	24.1.2		PULMOSMART 400 6/400 MCG CAPSULE 30	PULMOSMART	ALKEM LABORATORIES LTD.	6/400 MCG	30	CAPSULE	142.86	21112279	1.11%	1.11%	Y	4.76	4.76
11	24.1.2		QUIKHALE FB 6/400 MCG ROTACAP 40	QUIKHALE FB	INTAS PHARMACEUTICALS LTD	6/400 MCG	40	ROTACAP	192	17305182	0.91%	0.91%	N	4.80	

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									3
	24.1.1	Budesonide	Inhalation 100mcg	Per Metered dose		Sum of MAT value considered for price calculation (in Lakhs)									2,304.01
		MDI	(P,S,T)			Sum of PTR per unit considered for price calculation									3.50
						Number of Packs considered									3
						Average PTR									1.17
			Current Ceiling Price	**1.58**	**Per Metered dose**	Add : 16% Retailer Margin									0.19
			Maximum Permissible PTR	**1.36**		Ceiling Price (without GST)									1.35
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									7.41%
						Final Ceiling Price (without GST)									1.35
											Minimum Price (Rs.)				1.12
											Maximum Price (Rs.)				1.26
											Average of all considered (Rs.)				1.17
											Ceiling Price (Rs.)				1.35
											Reduction from current ceiling price				14.56%
A. List of items under consideration									TOTAL MAT	**23,12,04,362**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.1	Budesonide	BUDATE 100 MCG INHALER 200 MDI	BUDATE	LUPIN LTD	100 MCG	200	Per MDI	224.49	32845356	14.21%	14.21%	Y	1.12	1.12
2	24.1.1		BUDECORT 100 MCG INHALER 200 MDI	BUDECORT	CIPLA LTD.	100 MCG	200	Per MDI	252.8	187305221	81.01%	81.01%	Y	1.26	1.26
3	24.1.1		DERINIDE CFC FREE 100 MCG INHALER 200 I	DERINIDE	ZYDUS CADILA - ZHL	100 MCG	200	Per MDI	224.49	10250213	4.43%	4.43%	Y	1.12	1.12
4	24.1.1		NEBZMART 100 MCG INHALER 1	NEBZMART	GLENMARK PHARMACEUTICALS LTD	100 MCG	1	Per MDI	3571.43	803572	0.35%	0.35%	N	3571.43	

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									3
	24.1.1	Budesonide	Inhalation 200mcg	Per Metered dose		Sum of MAT value considered for price calculation (in Lakhs)									3,035.65
		MDI	(P,S,T)			Sum of PTR per unit considered for price calculation									4.89
						Number of Packs considered									3
						Average PTR									1.63
			Current Ceiling Price	**2.20**	**Per Metered dose**	Add : 16% Retailer Margin									0.26
			Maximum Permissible PTR	**1.89**		Ceiling Price (without GST)									1.89
			(S.O. 1573(E) dated 31.03.2023 and S.O 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									6.86%
						Final Ceiling Price (without GST)									1.89
											Minimum Price (Rs.)				1.57
											Maximum Price (Rs.)				1.75
											Average of all considered (Rs.)				1.63
											Ceiling Price (Rs.)				1.89
											Reduction from current ceiling price				14.09%
A. List of items under consideration									TOTAL MAT	**30,35,64,789**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.1	Budesonide	BUDATE 200 MCG INHALER 200 MDI	BUDATE	LUPIN LTD	200 MCG	200	Per MDI	313.59	24437251	8.05%	8.05%	Y	1.57	1.57
2	24.1.1		BUDECORT 200 MCG INHALER 200 MDI	BUDECORT	CIPLA LTD.	200 MCG	200	Per MDI	350.4	224550877	73.97%	73.97%	Y	1.75	1.75
3	24.1.1		DERINIDE CFC FREE 200 MCG INHALER 200 M	DERINIDE	ZYDUS CADILA - ZHL	200 MCG	200	Per MDI	313.59	54576661	17.98%	17.98%	Y	1.57	1.57

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									3
	24.1.1	Budesonide	Inhalation 200mcg	Per dose		Sum of MAT value considered for price calculation (in Lakhs)									902.58
		DPI	(P,S,T)			Sum of PTR per unit considered for price calculation									8.05
						Number of Packs considered									3
						Average PTR									2.68
			Current Ceiling Price	**3.60**	**Per dose**	Add : 16% Retailer Margin									0.43
			Maximum Permissible PTR	**3.10**		Ceiling Price (without GST)									3.11
			(S.O. 1573(E) dated 31.03.2023 and S.O 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									6.50%
						Final Ceiling Price (without GST)									3.11
											Minimum Price (Rs.)				2.31
											Maximum Price (Rs.)				2.87
											Average of all considered (Rs.)				2.68
											Ceiling Price (Rs.)				3.11
											Reduction from current ceiling price				13.61%
A. List of items under consideration									TOTAL MAT	**9,02,58,115**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	24.1.1	Budesonide	BUDATE 200 MCG TRANSCAPS 30	BUDATE	LUPIN LTD	200 MCG	30	TRANSCAPS	86.14	8754701	9.70%	9.70%	Y	2.87	2.87
2	24.1.1		BUDECORT 200 MCG ROTACAP 30	BUDECORT	CIPLA LTD.	200 MCG	30	ROTACAP	86.16	65939688	73.06%	73.06%	Y	2.87	2.87
3	24.1.1		DERINIDE 200 MCG RESPICAP 30	DERINIDE	ZYDUS CADILA - ZHL	200 MCG	30	RESPICAP	69.44	15563726	17.24%	17.24%	Y	2.31	2.31

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	16.1	Budesonide	Nasal spray 100mcg/dose	Per Dose		Sum of MAT value considered for price calculation (in Lakhs)									147.65
			(P,S,T)			Sum of PTR per unit considered for price calculation									0.72
						Number of Packs considered									1
						Average PTR									0.72
						Less: Reduction as per monopoly conditions									0.05
						PTR after reduction									0.67
			Current Ceiling Price	**1.13**	**Per Dose**	Add : 16% Retailer Margin									0.11
			Maximum Permissible PTR	**0.97**		Ceiling Price (without GST)									0.78
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									6.85%
						Final Ceiling Price (without GST)									0.78
											Minimum Price (Rs.)				0.72
											Maximum Price (Rs.)				0.72
											Average of all considered (Rs.)				0.72
											Ceiling Price (Rs.)				0.78
											Reduction from current ceiling price				30.97%
									TOTAL MAT	**1,47,64,917**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	16.1	Budesonide	BUDENASE AQ 100 MCG NASAL SPRAY	BUDENASE AQ	CIPLA LTD.	100 MCG	150	NASAL SP	108.36	14764917	100.00%	100.00%	Y	0.72	0.72
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Budesonide	Respirator solution for use in nebulizer1mg/mL						1577(E) dated 31.03.2023					10.22%
		2	Budesonide	Respirator solution for use in nebulizer 0.5mg/mL						1577(E) dated 31.03.2023					3.28%
		3	Budesonide	Inhalation (MDI) 100mcg/dose						Uploaded in current lot					7.41%
		4	Budesonide	Inhalation (MDI) 200mcg/dose						Uploaded in current lot					6.86%
		5	Budesonide	Inhalation (DPI) 200mcg/dose						Uploaded in current lot					6.50%
										Average reduction					**6.85%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	4.2.10 &	Snake venom antiserum	As licensed	10ml Vial		Sum of MAT value considered for price calculation (in Lakhs)									878.89
	19.2.7	Soluble/ liquid polyvalent	(P,S,T)			Sum of PTR per unit considered for price calculation									334.92
						Number of Packs considered									1
						Average PTR									334.92
						Less: Reduction as per monopoly conditions									5.33
						PTR after reduction									329.59
			Current Ceiling Price	**538.70**	**10ml Pack**	Add : 16% Retailer Margin									52.74
			Maximum Permissible PTR	**464.39**		Ceiling Price (without GST)									382.33
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									1.59%
						Final Ceiling Price (without GST)									382.33
											Minimum Price (Rs.)				334.92
											Maximum Price (Rs.)				334.92
											Average of all considered (Rs.)				334.92
											Ceiling Price (Rs.)				382.33
											Reduction from current ceiling price				29.03%
A. List of items under consideration									TOTAL MAT	**8,78,90,179**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size (Vial)**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	4.2.10 &	Snake venom antiserum-	ASVS INJECTION 10 ML	ASVS	BHARAT SERUMS & VACCINES LTD		1	Each Vial of 10ml	334.92	87889222	100.00%	100.00%	Y	334.92	334.92
2	19.2.7	Soluble/ Liquid polyvalent	SNAKE ANTIVENIN INJECTION 10	SNAKE ANTIVENIN	BIOLOGICAL E LTD		1	Each Vial of 10ml	319.2	958	0.00%	0.00%	N	319.20	

B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Snake venom antiserum Lyophilized polyvalent	As licensed 10ml pack						Uploaded with current sheet					1.59%
										Average reduction					**1.59%**

Computation of Ceiling Price based on Oct, 23 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	4.2.4	Desferrioxamine	Powder for injection 500mg	Each Vial		Sum of MAT value considered for price calculation (in Lakhs)									4.78
			(P,S,T)			Sum of PTR per unit considered for price calculation									172.57
						Number of Packs considered									1
						Average PTR									172.57
						Less: Reduction as per monopoly conditions									9.95
						PTR after reduction									162.62
			Current Ceiling Price	**200.19**	**Each Pack**	Add : 16% Retailer Margin									26.02
			Maximum Permissible PTR	**172.57**		Ceiling Price (without GST)									188.64
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									5.77%
						Final Ceiling Price (without GST)									188.64
											Minimum Price (Rs.)				172.57
											Maximum Price (Rs.)				172.57
											Average of all considered (Rs.)				172.57
											Ceiling Price (Rs.)				188.64
											Reduction from current ceiling price				5.77%
A. List of items under consideration									TOTAL MAT	**4,78,417**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size (Vial)**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	4.2.4	Desferrioxamine	DESFERAL 500MG INJECTION	DESFERAL	NOVARTIS INDIA LTD	500MG	1	Each Vial	174.86	478417	100.00%	100.00%	Y	174.86	172.57
	Note: The PTR of item at S.N. 1 is higher than the Maximum Permissible PTR, therefore restricted to Maximum Permissible PTR														
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	N-acetylcysteine	Injection200 mg/mL						194(E) dated 11.01.2023					15.28%
		2	D-Penicillamine	Capsule250 mg						194(E) dated 11.01.2023					12.46%
		3	Pralidoxime chloride (2-PAM)	Injection 25mg/mL						194(E) dated 11.01.2023					1.68%
		4	Neostigmine	Injection0.5mg/mL						194(E) dated 11.01.2023					6.20%
		5	Atropine	Injection0.6mg/mL						879(E) dated 24.02.2023					7.05%
		6	Snake venom antiserum	Soluble/ liquid polyvalent -Aslicensed						Uploaded with current sheet					1.59%
		7	Snake venom antiserum	Lyophilized polyvalent -Aslicensed						Uploaded with current sheet					1.59%

		8	Naloxone	Injection0.4mg/mL					194(E) dated 11.01.2023					0.29%
									Average reduction					**5.77%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									2
	10.5.1	Acetyl Salicylic Acid	Tablet 325 mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									3,369.70
			(P,S,T)			Sum of PTR per unit considered for price calculation									1.16
						Number of Packs considered									2
						Average PTR									0.58
			Current Ceiling Price	**0.68**	**Per Tablet**	Add : 16% Retailer Margin									0.09
			Maximum Permissible PTR	**0.58**		Ceiling Price (without GST)									0.67
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									0.00%
						Final Ceiling Price (without GST)									0.67
											Minimum Price (Rs.)				0.58
											Maximum Price (Rs.)				0.58
											Average of all considered (Rs.)				0.58
											Ceiling Price (Rs.)				0.67
											Reduction from current ceiling price				1.47%
									TOTAL MAT	**33,69,69,826**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	10.5.1	Acetyl salicylic acid	DISPRIN (RECKITT) 325 MG TAB	DISPRIN (RECKI	RECKITT BENCKISER	325MG	10	TABLET	8.62	330758020	98.16%	98.16%	Y	0.86	0.58
2	10.5.1	Acetyl salicylic acid	ECOSPRIN 325 MG TABLET 14	ECOSPRIN	USV PVT LTD	325MG	14	TABLET	11.47	6211806	1.84%	1.84%	Y	0.82	0.58
		Note: The PTR of item at S.N. 1 & 2 are higher than the Maximum Permissible PTR, therefore restricted to Maximum Permissible PTR.													

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									3
	6.7.1.6	Tenofovir Disproxil Fumarate (A) +Lamivudine (B) +Dolutegravir (C)	Tablet 300 mg (A) + 300 mg (B) + 50 mg (C) (P,S,T)	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									7,357.61
						Sum of PTR per unit considered for price calculation									396.47
						Number of Packs considered									4
						Average PTR									99.12
			Newly Added in NLEM 2022			Add : 16% Retailer Margin									15.86
						Ceiling Price (without GST)									114.98
						% Reduction with compared to Highest Price									9.10%
						Final Ceiling Price (without GST)									114.98
											Minimum Price (Rs.)				91.19
											Maximum Price (Rs.)				109.04
											Average of all considered (Rs.)				99.12
											Ceiling Price (Rs.)				114.98
									TOTAL MAT	**73,57,61,236**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	6.7.1.6	DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR | J5B45	ACRIPTEGA 50/300/300 MG TABLET 30	ACRIPTEGA	MYLAN	50/300/30	30	TABLET	2735.71	7591595	1.03%	1.03%	Y	91.19	91.19
2			VIROPIL 50/300/300 MG TABLET 30	VIROPIL	EMCURE PHARMACEUTICALS LTD	50/300/30	30	TABLET	2943.57	573666470	77.97%	95.82%	Y	98.12	98.12
3			VIROPIL 50/300/300 MG TABLET 90	VIROPIL	EMCURE PHARMACEUTICALS LTD	50/300/30	90	TABLET	8830.71	131365642	17.85%	95.82%	Y	98.12	98.12
4			XAPAVIR-LT 50/300/300 MG TABLET 28	XAPAVIR-LT	NATCO PHARMA LTD	50/300/30	28	TABLET	3053.25	23137529	3.14%	3.14%	Y	109.04	109.04

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	8.1.4	Folic Acid	Capsule 5mg	Per Capsule		Sum of MAT value considered for price calculation (in Lakhs)									5.58
			(P,S,T)			Sum of PTR per unit considered for price calculation									4.99
						Number of Packs considered									1
						Average PTR									4.99
						Less: Reduction as per monopoly conditions									0.64
						PTR after reduction									4.35
			Current Ceiling Price	**7.02**	**Per Capsule**	Add : 16% Retailer Margin									0.70
			Maximum Permissible PTR	**6.05**		Ceiling Price (without GST)									5.04
			(S.O. 1573(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									12.87%
						Final Ceiling Price (without GST)									5.04
											Minimum Price (Rs.)				4.99
											Maximum Price (Rs.)				4.99
											Average of all considered (Rs.)				4.99
											Ceiling Price (Rs.)				5.04
											Reduction from current ceiling price				28.21%
									TOTAL MAT	**5,57,518**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	8.1.4	Folic Acid	AFOL 5 MG CAPSULE 10	AFOL	LINCOLN PHARMACEUTICALS LTD	5 MG	10	CAPSULE	49.93	557518	100.00%	100.00%	Y	4.99	4.99
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	FolicAcid	Tablet5 mg						1577(E) dated 31.03.2023					12.87%
										Average reduction					**12.87%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	7.1.25	Imatinib	Capsule 400mg	Per Capsule		Sum of MAT value considered for price calculation (in Lakhs)									96.35
			(T)			Sum of PTR per unit considered for price calculation									102.23
						Number of Packs considered									1
						Average PTR									102.23
						Less: Reduction as per monopoly conditions									23.39
						PTR after reduction									78.84
			Current Ceiling Price	**317.99**	**Per Capsule**	Add : 16% Retailer Margin									12.61
			Maximum Permissible PTR	**274.12**		Ceiling Price (without GST)									91.46
			(S.O. 1573(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									22.88%
						Final Ceiling Price (without GST)									91.46
											Minimum Price (Rs.)				102.23
											Maximum Price (Rs.)				102.23
											Average of all considered (Rs.)				102.23
											Ceiling Price (Rs.)				91.46
											Reduction from current ceiling price				71.24%
A. List of items under consideration									TOTAL MAT	**96,35,240**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	7.1.25	Imatinib	SAMITIB 400 MG CAPSULE 10	SAMITIB	SAMARTH LIFE SCIENCES PVT LTD	400 MG	10	CAPSULE	1022.25	9635240	100.00%	100.00%	Y	102.23	102.23
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Imatinib	Tablet100mg						87(E) dated 06.01.2023					27.62%
		2	Imatinib	Tablet400mg						194(E) dated 11.01.2023					30.26%
		3	Imatinib	Capsule 100mg						1577(E) dated 31.03.2023					10.75%
										Average reduction					**22.88%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	6.3.3 &	Rifampicin	Tablet 300mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									3.59
	6.4.15		(S,T)			Sum of PTR per unit considered for price calculation									3.14
						Number of Packs considered									1
						Average PTR									3.14
						Add : 16% Retailer Margin									0.50
			Current Ceiling Price	**3.66**	**Per Tablet**	Ceiling Price (without GST)									3.64
			Maximum Permissible PTR	**3.15**		% Reduction with compared to Highest Price									0.00%
			(S.O. 1573(E) dated 31.03.2023) & 4663(E) dated 25.10.2023)			Final Ceiling Price (without GST)									3.64
											Minimum Price (Rs.)				3.14
											Maximum Price (Rs.)				3.14
											Average of all considered (Rs.)				3.14
											Ceiling Price (Rs.)				3.64
											Reduction from current ceiling price				0.48%
									TOTAL MAT	**3,58,823**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR (Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
	6.3.3 &	Rifampicin	MACOX 300 MG TABLET 6	MACOX	MACLEODS PHARMACEUTICALS PVT.LTD	300 MG	6	TABLET	18.86	3,58,797.92	99.99%	99.99%	Y	3.14	3.14
1	6.4.15		RF 300 MG TABLET 10	RF	SUNIJ PHARMA PVT LTD	300 MG	10	TABLET	25.16	25	0.01%	0.01%	N	2.52	

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013

						Number of Companies consisting of Market Share of 1% & Above									1
	6.7.4.3	Darunavir (A) + Ritonavir (B)	Tablet 600 mg (A) + 100 mg (B)	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									1,603.62
			(S,T)			Sum of PTR per unit considered for price calculation									138.02
						Number of Packs considered									1
						Average PTR									138.02
						Less: Reduction as per monopoly conditions									11.77
						PTR after reduction									126.25
			Newly Added in NLEM 2022			Add : 16% Retailer Margin									20.20
						Ceiling Price (without GST)									146.45
						% Reduction with compared to Highest Price									8.53%
						Final Ceiling Price (without GST)									146.45
											Minimum Price (Rs.)				138.02
											Maximum Price (Rs.)				138.02
											Average of all considered (Rs.)				138.02
											Ceiling Price (Rs.)				146.45
									TOTAL MAT	**16,07,95,214**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	6.7.4.3	Darunavir (A) + Ritonavir (B)	DARUVIR R 600/100 MG TABLET 60	DARUVIR R	CIPLA LTD.	600/100 M	60	TABLET	6,993.60	433603	0.27%	0.27%	N	116.56	
2			VIREM R 600/100 MG TABLET 60	VIREM R	EMCURE PHARMACEUTICALS LTD	600/100 M	60	TABLET	8281.43	160361611	99.73%	99.73%	Y	138.02	138.02

B. Computation of Average rate of reduction under Monopoly

S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**	**S.O. Number & date**	**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
1	Abacavir (A) +Lamivudine(B)	Tablet600mg(A)+300mg(B)	5938(E) dated 19.12.2022	23.91%
2	TenofovirDisproxilFumarate (A) +Lamivudine(B)+Efavirenz(C)	Tablet300mg(A)+ 300mg(B)+600mg(C)	194(E) dated 11.01.2023	4.33%
3	Dolutegravir	Tablet50mg	5939(E) dated 19.12.2022	4.16%
4	Atazanavir (A) +Ritonavir(B)	Tablet300mg(A)+Tablet100mg(B)	87(E) dated 06.01.2023	6.87%
5	Zidovudine (A) +Lamivudine (B) +Nevirapine(C)	Tablet300mg(A)+150mg(B)+200mg (c)	484(E) dated 02.02.2023	6.98%
6	Efavirenz	Tablet 600mg	194(E) dated 11.01.2023	4.69%
7	Lamivudine	Tablet100mg	5939(E) dated 19.12.2022	22.25%
8	Zidovudine (A) +Lamivudine(B)	Tablet300mg(A)+150mg(B)	87(E) dated 06.01.2023	4.97%
9	Lopinavir (A) +Ritonavir(B)	Tablet200 mg(A)+50mg(B)	194(E) dated 11.01.2023	15.43%
10	Abacavir	Tablet 300 mg	5938(E) dated 19.12.2022	1.18%
11	TenofovirDisproxilFumarate (A)+Lamivudine(B)	Tablet300mg(A)+300mg(B)	194(E) dated 11.01.2023	6.63%
12	Azithromycin	Tablet 1000mg	1578(E) dated 31.03.2023	14.40%
13	Lamivudine	Tablet150mg	5939(E) dated 19.12.2022	12.88%
14	Efavirenz	Capsule 200 mg	2124(E) dated 04.05.2023	4.69%
15	Clindamycin	Tablet300mg	194(E) dated 11.01.2023	0.00%
16	Ritonavir	Tablet100mg	484(E) dated 02.02.2023	1.12%
17	Nevirapine	Tablet200 mg	5938(E) dated 19.12.2022	7.93%
18	Darunavir	Tablet600mg	5938(E) dated 19.12.2022	1.80%
19	Efavirenz	Tablet 200 mg (p)	1577(E) dated 31.03.2023	4.69%
20	Raltegravir	Tablet400mg	5938(E) dated 19.12.2022	1.92%
21	Cefotaxime	Injection1000mg	87(E) dated 06.01.2023	4.62%
22	Acyclovir	Injection250mg	194(E) dated 11.01.2023	3.61%
23	TenofovirDisproxilFumarate(TDF)*	Tablet300mg	194(E) dated 11.01.2023	14.34%

		24	Valganciclovir	Tablet 450mg						5939(E) dated 19.12.2022				30.76%
		25	TenofovirDisproxilFumarate (A) +Lamivudine(B)+Efavirenz(C)	Tablet300mg(A)+ 300mg(B)+50mg(C)						Uploaded in current lot				9.10%
										Average reduction				**8.53%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	7.1.12	Chlorambucil	Tablet 2mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									14.61
			(T)			Sum of PTR per unit considered for price calculation									33.33
						Number of Packs considered									1
						Average PTR									33.33
						Less: Reduction as per monopoly conditions									6.49
						PTR after reduction									26.84
			Current Ceiling Price	**45.95**	**Per Tablet**	Add : 16% Retailer Margin									4.29
			Maximum Permissible PTR	**39.61**		Ceiling Price (without GST)									31.13
			(S.O. 1573(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									19.48%
						Final Ceiling Price (without GST)									31.13
											Minimum Price (Rs.)				33.33
											Maximum Price (Rs.)				33.33
											Average of all considered (Rs.)				33.33
											Ceiling Price (Rs.)				31.13
											Reduction from current ceiling price				32.25%
A. List of items under consideration									TOTAL MAT	**14,61,000**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	7.1.12	Chlorambucil	CELKERAN 2 MG TABLET 30	CELKERAN	CELON LABS	2 MG	30	TABLET	1000	1461000	100.00%	100.00%	Y	33.33	33.33
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Temozolomide	Capsule20 mg						5938(E) dated 19.12.2022					11.76%
		2	Lenalidomide	Capsule5mg						5938(E) dated 19.12.2022					10.36%
		3	Temozolomide	Capsule250mg						5938(E) dated 19.12.2022					19.62%
		4	Capecitabine	Tablet500mg						5938(E) dated 19.12.2022					22.71%
		5	L-Asparaginase	Powder for Injection 5000 KU						87(E) dated 06.01.2023					1.93%
		6	Docetaxel	PowderforInjection20mg						87(E) dated 06.01.2023					23.03%
		7	L-Asparaginase	Powderfor Injection10000KU						87(E) dated 06.01.2023					7.92%
		8	Gemcitabine	PowderforInjection1000mg						87(E) dated 06.01.2023					15.33%
		9	Hydroxyurea	Capsule500mg						87(E) dated 06.01.2023					18.10%
		10	Imatinib	Tablet100mg						87(E) dated 06.01.2023					27.62%
		11	Dacarbazine	PowderforInjection200mg						87(E) dated 06.01.2023					16.49%
		12	Gemcitabine	Powder for Injection 200 mg						87(E) dated 06.01.2023					10.89%
		13	Thalidomide	Capsule100mg						87(E) dated 06.01.2023					12.00%
		14	Thalidomide	Capsule50 mg						87(E) dated 06.01.2023					15.35%
		15	Methotrexate	Tablet 2.5mg						87(E) dated 06.01.2023					3.88%
		16	Methotrexate	Tablet 10mg						87(E) dated 06.01.2023					5.24%
		17	Bleomycin	PowderforInjection15units						194(E) dated 11.01.2023					12.02%
		18	Etoposide	Capsule50mg						194(E) dated 11.01.2023					9.84%
		19	Etoposide	Injection20mg/mL						194(E) dated 11.01.2023					7.71%
		20	Docetaxel	PowderforInjection80mg						194(E) dated 11.01.2023					26.68%
		21	Imatinib	Tablet400mg						194(E) dated 11.01.2023					30.26%

		22	Trastuzumab	Injection440mg/50mL						194(E) dated 11.01.2023					22.13%
		23	Bortezomib	Powderfor Injection2mg						194(E) dated 11.01.2023					56.35%
		24	Temozolomide	Capsule100mg						194(E) dated 11.01.2023					32.06%
		25	6-Mercaptopurine	Tablet50mg						194(E) dated 11.01.2023					22.01%
		26	Cyclophosphamide	Powder for Injection 500mg						194(E) dated 11.01.2023					11.72%
		27	Dacarbazine	PowderforInjection500mg						194(E) dated 11.01.2023					19.87%
		28	Cytosinearabinoside	Injection1000mg/vial						194(E) dated 11.01.2023					15.27%
		29	Bendamustine hydrochloride	Injection100 mg/vial						195(E) dated 11.01.2023					43.97%
		30	Lenalidomide	Capsule25 mg						195(E) dated 11.01.2023					17.23%
		31	Oxaliplatin	Injection 5 mg/mL in 10 mL vial						194(E) dated 11.01.2023					25.61%
		32	Vincristine	Injection1mg/mL						484(E) dated 02.02.2023					8..71%
		33	Cytosinearabinoside	Injection500mg/vial						484(E) dated 02.02.2023					9.89%
		34	Cytosinearabinoside	Injection100mg/vial						484(E) dated 02.02.2023					43.57%
		35	Gefitinib	Tablet250mg						484(E) dated 02.02.2023					50.41%
		36	Rituximab	Injection10mg/mL						484(E) dated 02.02.2023					19.33%
		37	Carboplatin	Injection10mg/mL						879(E) dated 24.02.2023					9.50%
		38	Calcium folinate	Tablet 15mg						879(E) dated 24.02.2023					6.37%
		39	Actinomycin D	Powder for Injection 0.5mg						879(E) dated 24.02.2023					1.74%
		40	Cisplatin	Injection1mg/mL						879(E) dated 24.02.2023					17.35%
		41	Ifosfamide	PowderforInjection2000mg						1577(E) dated 31.03.2023					18.26%
		42	Doxorubicin	Injection2mg/mL						1577(E) dated 31.03.2023					23.45%
		43	Cyclophosphamide	Tablet 50mg						1577(E) dated 31.03.2023					11.72%
		44	Imatinib	Capsule 100mg						1577(E) dated 31.03.2023					10.75%
		45	Paclitaxel	Injection100mg/16.7 mL						1577(E) dated 31.03.2023					15.85%
		46	Methotrexate	Tablet 5mg						1577(E) dated 31.03.2023					2.42%
		47	Ifosfamide	Powder for Injection 1000mg						1577(E) dated 31.03.2023					18.26%
		48	Irinotecan HCltrihydrate	Solution for injection 20mg/mL						1579(E) dated 31.03.2023					75.21%
		49	Temozolomide	Tablet 20mg						4886(E) dated 10.11.2023					21.15%
		50	Temozolomide	Tablet 250mg						4886(E) dated 10.11.2023					21.15%
		51	Imatinib	Capsule 400mg						Uploaded in Current Lot					22.88%
										Average reduction					**19.48%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	7.1.29	Melphalan	Tablet 5mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									9.89
			(T)			Sum of PTR per unit considered for price calculation									92.04
						Number of Packs considered									1
						Average PTR									92.04
						Less: Reduction as per monopoly conditions									17.93
						PTR after reduction									74.11
			Current Ceiling Price	**209.48**	**Per Tablet**	Add : 16% Retailer Margin									11.86
			Maximum Permissible PTR	**180.58**		Ceiling Price (without GST)									85.96
			(S.O. 1573(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									19.48%
						Final Ceiling Price (without GST)									85.96
											Minimum Price (Rs.)				92.04
											Maximum Price (Rs.)				92.04
											Average of all considered (Rs.)				92.04
											Ceiling Price (Rs.)				85.96
											Reduction from current ceiling price				58.97%
A. List of items under consideration									TOTAL MAT	**9,89,430**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	7.1.29	Melphalan	ALKACEL 5 MG TABLET 25	ALKACEL	CELON LABS	5 MG	25	TABLET	2301	989430	100.00%	100.00%	Y	92.04	92.04
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Temozolomide	Capsule20 mg						5938(E) dated 19.12.2022					11.76%
		2	Lenalidomide	Capsule5mg						5938(E) dated 19.12.2022					10.36%
		3	Temozolomide	Capsule250mg						5938(E) dated 19.12.2022					19.62%
		4	Capecitabine	Tablet500mg						5938(E) dated 19.12.2022					22.71%
		5	L-Asparaginase	Powder for Injection 5000 KU						87(E) dated 06.01.2023					1.93%
		6	Docetaxel	PowderforInjection20mg						87(E) dated 06.01.2023					23.03%
		7	L-Asparaginase	Powderfor Injection10000KU						87(E) dated 06.01.2023					7.92%
		8	Gemcitabine	PowderforInjection1000mg						87(E) dated 06.01.2023					15.33%
		9	Hydroxyurea	Capsule500mg						87(E) dated 06.01.2023					18.10%
		10	Imatinib	Tablet100mg						87(E) dated 06.01.2023					27.62%
		11	Dacarbazine	PowderforInjection200mg						87(E) dated 06.01.2023					16.49%
		12	Gemcitabine	Powder for Injection 200 mg						87(E) dated 06.01.2023					10.89%
		13	Thalidomide	Capsule100mg						87(E) dated 06.01.2023					12.00%
		14	Thalidomide	Capsule50 mg						87(E) dated 06.01.2023					15.35%
		15	Methotrexate	Tablet 2.5mg						87(E) dated 06.01.2023					3.88%
		16	Methotrexate	Tablet 10mg						87(E) dated 06.01.2023					5.24%
		17	Bleomycin	PowderforInjection15units						194(E) dated 11.01.2023					12.02%
		18	Etoposide	Capsule50mg						194(E) dated 11.01.2023					9.84%
		19	Etoposide	Injection20mg/mL						194(E) dated 11.01.2023					7.71%
		20	Docetaxel	PowderforInjection80mg						194(E) dated 11.01.2023					26.68%
		21	Imatinib	Tablet400mg						194(E) dated 11.01.2023					30.26%
		22	Trastuzumab	Injection440mg/50mL						194(E) dated 11.01.2023					22.13%
		23	Bortezomib	Powderfor Injection2mg						194(E) dated 11.01.2023					56.35%
		24	Temozolomide	Capsule100mg						194(E) dated 11.01.2023					32.06%

		25	6-Mercaptopurine	Tablet50mg						194(E) dated 11.01.2023					22.01%
		26	Cyclophosphamide	Powder for Injection 500mg						194(E) dated 11.01.2023					11.72%
		27	Dacarbazine	PowderforInjection500mg						194(E) dated 11.01.2023					19.87%
		28	Cytosinearabinoside	Injection1000mg/vial						194(E) dated 11.01.2023					15.27%
		29	Bendamustine hydrochloride	Injection100 mg/vial						195(E) dated 11.01.2023					43.97%
		30	Lenalidomide	Capsule25 mg						195(E) dated 11.01.2023					17.23%
		31	Oxaliplatin	Injection 5 mg/mL in 10 mL vial						194(E) dated 11.01.2023					25.61%
		32	Vincristine	Injection1mg/mL						484(E) dated 02.02.2023					8..71%
		33	Cytosinearabinoside	Injection500mg/vial						484(E) dated 02.02.2023					9.89%
		34	Cytosinearabinoside	Injection100mg/vial						484(E) dated 02.02.2023					43.57%
		35	Gefitinib	Tablet250mg						484(E) dated 02.02.2023					50.41%
		36	Rituximab	Injection10mg/mL						484(E) dated 02.02.2023					19.33%
		37	Carboplatin	Injection10mg/mL						879(E) dated 24.02.2023					9.50%
		38	Calcium folinate	Tablet 15mg						879(E) dated 24.02.2023					6.37%
		39	Actinomycin D	Powder for Injection 0.5mg						879(E) dated 24.02.2023					1.74%
		40	Cisplatin	Injection1mg/mL						879(E) dated 24.02.2023					17.35%
		41	Ifosfamide	PowderforInjection2000mg						1577(E) dated 31.03.2023					18.26%
		42	Doxorubicin	Injection2mg/mL						1577(E) dated 31.03.2023					23.45%
		43	Cyclophosphamide	Tablet 50mg						1577(E) dated 31.03.2023					11.72%
		44	Imatinib	Capsule 100mg						1577(E) dated 31.03.2023					10.75%
		45	Paclitaxel	Injection100mg/16.7 mL						1577(E) dated 31.03.2023					15.85%
		46	Methotrexate	Tablet 5mg						1577(E) dated 31.03.2023					2.42%
		47	Ifosfamide	Powder for Injection 1000mg						1577(E) dated 31.03.2023					18.26%
		48	Irinotecan HCltrihydrate	Solution for injection 20mg/mL						1579(E) dated 31.03.2023					75.21%
		49	Temozolomide	Tablet 20mg						4886(E) dated 10.11.2023					21.15%
		50	Temozolomide	Tablet 250mg						4886(E) dated 10.11.2023					21.15%
		51	Imatinib	Capsule 400mg						Uploaded in Current Lot					22.88%
										Average reduction					**19.48%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	7.1.29	Melphalan	Tablet 2mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									15.66
			(T)			Sum of PTR per unit considered for price calculation									97.70
						Number of Packs considered									1
						Average PTR									97.70
						Less: Reduction as per monopoly conditions									19.04
						PTR after reduction									78.66
			Current Ceiling Price	**122.13**	**Per Tablet**	Add : 16% Retailer Margin									12.59
			Maximum Permissible PTR	**105.28**		Ceiling Price (without GST)									91.25
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									19.48%
						Final Ceiling Price (without GST)									91.25
											Minimum Price (Rs.)				97.70
											Maximum Price (Rs.)				97.70
											Average of all considered (Rs.)				97.70
											Ceiling Price (Rs.)				91.25
											Reduction from current ceiling price				25.28%
A. List of items under consideration									TOTAL MAT	**15,66,306**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	7.1.29	Melphalan	ALKACEL 2 MG TABLET 25	ALKACEL	CELON LABS	2 MG	25	TABLET	2442.47	1566306	100.00%	100.00%	Y	97.70	97.70
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Temozolomide	Capsule20 mg						5938(E) dated 19.12.2022					11.76%
		2	Lenalidomide	Capsule5mg						5938(E) dated 19.12.2022					10.36%
		3	Temozolomide	Capsule250mg						5938(E) dated 19.12.2022					19.62%
		4	Capecitabine	Tablet500mg						5938(E) dated 19.12.2022					22.71%
		5	L-Asparaginase	Powder for Injection 5000 KU						87(E) dated 06.01.2023					1.93%
		6	Docetaxel	PowderforInjection20mg						87(E) dated 06.01.2023					23.03%
		7	L-Asparaginase	Powderfor Injection10000KU						87(E) dated 06.01.2023					7.92%
		8	Gemcitabine	PowderforInjection1000mg						87(E) dated 06.01.2023					15.33%
		9	Hydroxyurea	Capsule500mg						87(E) dated 06.01.2023					18.10%
		10	Imatinib	Tablet100mg						87(E) dated 06.01.2023					27.62%
		11	Dacarbazine	PowderforInjection200mg						87(E) dated 06.01.2023					16.49%
		12	Gemcitabine	Powder for Injection 200 mg						87(E) dated 06.01.2023					10.89%
		13	Thalidomide	Capsule100mg						87(E) dated 06.01.2023					12.00%
		14	Thalidomide	Capsule50 mg						87(E) dated 06.01.2023					15.35%
		15	Methotrexate	Tablet 2.5mg						87(E) dated 06.01.2023					3.88%
		16	Methotrexate	Tablet 10mg						87(E) dated 06.01.2023					5.24%
		17	Bleomycin	PowderforInjection15units						194(E) dated 11.01.2023					12.02%
		18	Etoposide	Capsule50mg						194(E) dated 11.01.2023					9.84%
		19	Etoposide	Injection20mg/mL						194(E) dated 11.01.2023					7.71%
		20	Docetaxel	PowderforInjection80mg						194(E) dated 11.01.2023					26.68%
		21	Imatinib	Tablet400mg						194(E) dated 11.01.2023					30.26%
		22	Trastuzumab	Injection440mg/50mL						194(E) dated 11.01.2023					22.13%

		23	Bortezomib	Powderfor Injection2mg						194(E) dated 11.01.2023					56.35%
		24	Temozolomide	Capsule100mg						194(E) dated 11.01.2023					32.06%
		25	6-Mercaptopurine	Tablet50mg						194(E) dated 11.01.2023					22.01%
		26	Cyclophosphamide	Powder for Injection 500mg						194(E) dated 11.01.2023					11.72%
		27	Dacarbazine	PowderforInjection500mg						194(E) dated 11.01.2023					19.87%
		28	Cytosinearabinoside	Injection1000mg/vial						194(E) dated 11.01.2023					15.27%
		29	Bendamustine hydrochloride	Injection100 mg/vial						195(E) dated 11.01.2023					43.97%
		30	Lenalidomide	Capsule25 mg						195(E) dated 11.01.2023					17.23%
		31	Oxaliplatin	Injection 5 mg/mL in 10 mL vial						194(E) dated 11.01.2023					25.61%
		32	Vincristine	Injection1mg/mL						484(E) dated 02.02.2023					8..71%
		33	Cytosinearabinoside	Injection500mg/vial						484(E) dated 02.02.2023					9.89%
		34	Cytosinearabinoside	Injection100mg/vial						484(E) dated 02.02.2023					43.57%
		35	Gefitinib	Tablet250mg						484(E) dated 02.02.2023					50.41%
		36	Rituximab	Injection10mg/mL						484(E) dated 02.02.2023					19.33%
		37	Carboplatin	Injection10mg/mL						879(E) dated 24.02.2023					9.50%
		38	Calcium folinate	Tablet 15mg						879(E) dated 24.02.2023					6.37%
		39	Actinomycin D	Powder for Injection 0.5mg						879(E) dated 24.02.2023					1.74%
		40	Cisplatin	Injection1mg/mL						879(E) dated 24.02.2023					17.35%
		41	Ifosfamide	PowderforInjection2000mg						1577(E) dated 31.03.2023					18.26%
		42	Doxorubicin	Injection2mg/mL						1577(E) dated 31.03.2023					23.45%
		43	Cyclophosphamide	Tablet 50mg						1577(E) dated 31.03.2023					11.72%
		44	Imatinib	Capsule 100mg						1577(E) dated 31.03.2023					10.75%
		45	Paclitaxel	Injection100mg/16.7 mL						1577(E) dated 31.03.2023					15.85%
		46	Methotrexate	Tablet 5mg						1577(E) dated 31.03.2023					2.42%
		47	Ifosfamide	Powder for Injection 1000mg						1577(E) dated 31.03.2023					18.26%
		48	Irinotecan HCltrihydrate	Solution for injection 20mg/mL						1579(E) dated 31.03.2023					75.21%
		49	Temozolomide	Tablet 20mg						4886(E) dated 10.11.2023					21.15%
		50	Temozolomide	Tablet 250mg						4886(E) dated 10.11.2023					21.15%
		51	Imatinib	Capsule 400mg						Uploaded in Current Lot					22.88%
										Average reduction					**19.48%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	6.7.1.8	Zidovudine	Tablet 300 mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)									64.56
			(S,T)			Sum of PTR per unit considered for price calculation									12.81
						Number of Packs considered									1
						Average PTR									12.81
						Less: Reduction as per monopoly conditions									1.09
						PTR after reduction									11.72
			Current Ceiling Price	**17.75**	**Per Tablet**	Add : 16% Retailer Margin									1.87
			Maximum Permissible PTR	**15.30**		Ceiling Price (without GST)									13.59
			(S.O. 1573(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									8.53%
						Final Ceiling Price (without GST)									13.59
											Minimum Price (Rs.)				12.81
											Maximum Price (Rs.)				12.81
											Average of all considered (Rs.)				12.81
											Ceiling Price (Rs.)				13.59
											Reduction from current ceiling price				23.44%
									TOTAL MAT	**64,55,702**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	6.7.1.8	Zidovudine	ZIDINE 300 MG TABLET 60	ZIDINE	EMCURE PHARMACEUTICALS LTD	300 MG	60	TABLET	768.86	6455702	100.00%	100.00%	Y	12.81	12.81

B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Abacavir (A) +Lamivudine(B)	Tablet600mg(A)+300mg(B)						5938(E) dated 19.12.2022					23.91%
		2	TenofovirDisproxilFumarate (A) +Lamivudine(B)+Efavirenz(C)	Tablet300mg(A)+ 300mg(B)+600mg(C)						194(E) dated 11.01.2023					4.33%
		3	Dolutegravir	Tablet50mg						5939(E) dated 19.12.2022					4.16%
		4	Atazanavir (A) +Ritonavir(B)	Tablet300mg(A)+Tablet100mg(B)						87(E) dated 06.01.2023					6.87%
		5	Zidovudine (A) +Lamivudine (B) +Nevirapine(C)	Tablet300mg(A)+150mg(B)+200mg (c)						484(E) dated 02.02.2023					6.98%
		6	Efavirenz	Tablet 600mg						194(E) dated 11.01.2023					4.69%
		7	Lamivudine	Tablet100mg						5939(E) dated 19.12.2022					22.25%
		8	Zidovudine (A) +Lamivudine(B)	Tablet300mg(A)+150mg(B)						87(E) dated 06.01.2023					4.97%
		9	Lopinavir (A) +Ritonavir(B)	Tablet200 mg(A)+50mg(B)						194(E) dated 11.01.2023					15.43%
		10	Abacavir	Tablet 300 mg						5938(E) dated 19.12.2022					1.18%
		11	TenofovirDisproxilFumarate (A)+Lamivudine(B)	Tablet300mg(A)+300mg(B)						194(E) dated 11.01.2023					6.63%
		12	Azithromycin	Tablet 1000mg						1578(E) dated 31.03.2023					14.40%
		13	Lamivudine	Tablet150mg						5939(E) dated 19.12.2022					12.88%
		14	Efavirenz	Capsule 200 mg						2124(E) dated 04.05.2023					4.69%
		15	Clindamycin	Tablet300mg						194(E) dated 11.01.2023					0.00%
		16	Ritonavir	Tablet100mg						484(E) dated 02.02.2023					1.12%
		17	Nevirapine	Tablet200 mg						5938(E) dated 19.12.2022					7.93%
		18	Darunavir	Tablet600mg						5938(E) dated 19.12.2022					1.80%
		19	Efavirenz	Tablet 200 mg (p)						1577(E) dated 31.03.2023					4.69%
		20	Raltegravir	Tablet400mg						5938(E) dated 19.12.2022					1.92%
		21	Cefotaxime	Injection1000mg						87(E) dated 06.01.2023					4.62%
		22	Acyclovir	Injection250mg						194(E) dated 11.01.2023					3.61%
		23	TenofovirDisproxilFumarate(TDF)*	Tablet300mg						194(E) dated 11.01.2023					14.34%
		24	Valganciclovir	Tablet 450mg						5939(E) dated 19.12.2022					30.76%
		25	TenofovirDisproxilFumarate (A) +Lamivudine(B)+Efavirenz(C)	Tablet300mg(A)+ 300mg(B)+50mg(C)						Uploaded in current lot					9.10%

									Average reduction					**8.53%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	23.5.3	Nicotine	Oral dosage form 2mg	Per Pastille		Sum of MAT value considered for price calculation (in Lakhs)									77.85
		(for nicotine	(P,S,T)			Sum of PTR per unit considered for price calculation									6.33
		replacement therapy)				Number of Packs considered									1
						Average PTR									6.33
						Less: Reduction as per monopoly conditions									0.19
						PTR after reduction									6.14
			New added medicine in the list of NLEM 2022			Add : 16% Retailer Margin									0.98
						Ceiling Price (without GST)									7.12
						% Reduction with compared to Highest Price									3.00%
						Final Ceiling Price (without GST)									7.12
											Minimum Price (Rs.)				6.33
											Maximum Price (Rs.)				6.33
											Average of all considered (Rs.)				6.33
											Ceiling Price (Rs.)				7.12
									TOTAL MAT	**77,85,305**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	23.5.3	Nicotine	NICLONZ 2 MG PASTILLES 10	NICLONZ	INTAS PHARMACEUTICALS LTD	2 MG	10	PASTILLES	63.28	7785305	100.00%	100.00%	Y	6.33	6.33

B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Nicotine(for nicotine replacement therapy)	OralDosageforms4mg Gum						1579(E)dt. 31.03.2023					3.39%
		2	Nicotine(for nicotine replacement therapy)	Oral Dosage forms 2mg Gum						1579(E)dt. 31.03.2023					0.76%
		3	Nicotine(for nicotine replacement therapy)	OralDosageforms2mg Lozenge						1579(E)dt. 31.03.2023					3.31%
		4	Nicotine(for nicotine replacement therapy)	OralDosageforms4mg Lozenge						1579(E)dt. 31.03.2023					4.55%
										Average reduction					**3.00%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	23.5.3	Nicotine	Oral dosage form 4mg	Per Pastille		Sum of MAT value considered for price calculation (in Lakhs)									36.39
		(for nicotine	(P,S,T)			Sum of PTR per unit considered for price calculation									6.96
		replacement therapy)				Number of Packs considered									1
						Average PTR									6.96
						Less: Reduction as per monopoly conditions									0.21
						PTR after reduction									6.75
			New added medicine in the list of NLEM 2022			Add : 16% Retailer Margin									1.08
						Ceiling Price (without GST)									7.83
						% Reduction with compared to Highest Price									3.00%
						Final Ceiling Price (without GST)									7.83
											Minimum Price (Rs.)				6.96
											Maximum Price (Rs.)				6.96
											Average of all considered (Rs.)				6.96
											Ceiling Price (Rs.)				7.83
									TOTAL MAT	**36,38,681**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	23.5.3	Nicotine	NICLONZ 4 MG PASTILLES 10	NICLONZ	INTAS PHARMACEUTICALS LTD	4 MG	10	PASTILLES	69.6	3638681	100.00%	100.00%	Y	6.96	6.96

B. Computation of Average rate of reduction under Monopoly

S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**	**S.O. Number & date**	**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
1	Nicotine(for nicotine replacement therapy)	OralDosageforms4mg Gum	1579(E)dt. 31.03.2023	3.39%
2	Nicotine(for nicotine replacement therapy)	Oral Dosage forms 2mg Gum	1579(E)dt. 31.03.2023	0.76%
3	Nicotine(for nicotine replacement therapy)	OralDosageforms2mg Lozenge	1579(E)dt. 31.03.2023	3.31%
4	Nicotine(for nicotine replacement therapy)	OralDosageforms4mg Lozenge	1579(E)dt. 31.03.2023	4.55%
			Average reduction	**3.00%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									1
	6.2.1.4	Benzathine benzylpenicillin	Powder for injection 12 lacs Units (P,S,T)	Each Vial		Sum of MAT value considered for price calculation (in Lakhs)									1,072.78
						Sum of PTR per unit considered for price calculation									19.50
						Number of Packs considered									1
						Average PTR									19.50
						Less: Reduction as per monopoly conditions									2.42
						PTR after reduction									17.08
			Current Ceiling Price	**22.70**	**Each Pack**	Add : 16% Retailer Margin									2.73
			Maximum Permissible PTR	**19.56**		Ceiling Price (without GST)									19.81
			(S.O. 1573(E) dated 31.03.2023)			% Reduction with compared to Highest Price									12.42%
						Final Ceiling Price (without GST)									19.81
											Minimum Price (Rs.)				19.50
											Maximum Price (Rs.)				19.50
											Average of all considered (Rs.)				19.50
											Ceiling Price (Rs.)				19.81
											Reduction from current ceiling price				12.73%
A. List of items under consideration									TOTAL MAT	**10,72,77,613**	100%			M3	
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	6.2.1.4	Benzathine benzylpenicillin	PENIDURE LA 1200000 IU INJECTIO	PENIDURE LA	PFIZER LTD	1200000 IU	1	Each Vial	19.5	107277613	100.00%	100.00%	Y	19.50	19.50
B. Computation of Average rate of reduction under Monopoly															
		S.No.	**Drug**	**Strength Route of Administration / Dosage Form & Packsize/Packing, if any**						**S.O. Number & date**					**Reduction with reference to the highest PTR under NLEM, 2022 (%)**
		1	Amoxicillin	Oral liquid 125 mg/5 mL (p)						1579(E) dated 31.03.2023					25.73%
		2	Amoxicillin	Capsule500mg						484(E) dated 02.02.2023					6.09%
		3	Amoxicillin	Capsule250mg						194(E) dated 11.01.2023					4.25%
		4	Amoxicillin	Powder for Injection 500 mg						1578(E) dated 31.03.2023					11.55%
		5	Amoxicillin	Oral liquid 250 mg/5 mL (p)						1577(E) dated 31.03.2023					0.42%
		6	Amoxicillin	Powder for Injection 250 mg						1578(E) dated 31.03.2023					11.55%
		7	Amoxicillin (A) +Clavulanicacid (B)	Tablet 500 mg (A) + 125 mg (B)						87(E) dated 06.01.2023					18.22%
		8	Amoxicillin (A) +Clavulanicacid (B)	Oral liquid 200 mg (A) + 28.5mg(B)/5 mL(p)						484(E) dated 02.02.2023					9.54%
		9	Amoxicillin (A) +Clavulanicacid (B)	Powder for Injection 1 g (A) +200mg (B)						87(E) dated 06.01.2023					7.97%
		10	Amoxicillin (A) +Clavulanicacid (B)	Powderfor Injection500mg(A)+100mg(B)						194(E) dated 11.01.2023					9.55%
		11	Amoxicillin (A) +Clavulanicacid (B)	DrySyrup125mg(A)+31.25(B)/5mL(p)						194(E) dated 11.01.2023					3.48%
		12	Ampicillin	Powder for Injection 500 mg						87(E) dated 06.01.2023					6.16%
		13	Azithromycin	Tablet500mg						484(E) dated 02.02.2023					4.18%
		14	Azithromycin	Capsule 500mg						2124(E) dated 04.05.2023					7.82%
		15	Azithromycin	Oral liquid 200 mg/5 mL (p)						484(E) dated 02.02.2023					10.90%
		16	Azithromycin	Tablet250mg						484(E) dated 02.02.2023					6.54%

		17	Azithromycin	PowderforInjection500mg					194(E) dated 11.01.2023				7.83%
		18	Azithromycin	Capsule250mg					1577(E) dated 31.03.2023				3.09%
		19	Cefadroxil	Tablet500mg					5938(E) dated 19.12.2022				3.86%
		20	Cefadroxil	Oralliquid125mg/5mL(p)					194(E) dated 11.01.2023				6.25%
		21	Cefixime	Tablet200mg					87(E) dated 06.01.2023				11.92%
		22	Cefixime	Oral liquid 50 mg/5 mL (p)					484(E) dated 02.02.2023				10.71%
		23	Cefixime	Oralliquid100mg/5mL(p)					484(E) dated 02.02.2023				3.70%
		24	Cefixime	Tablet400mg					5938(E) dated 19.12.2022				10.57%
		25	Cefixime	Capsule200mg					1577(E) dated 31.03.2023				18.34%
		26	Cefotaxime	PowderforInjection1000mg					87(E) dated 06.01.2023				4.62%
		27	Cefotaxime	Powder for Injection 500 mg					87(E) dated 06.01.2023				4.49%
		28	Cefotaxime	Powder for Injection 250 mg					87(E) dated 06.01.2023				6.13%
		29	Ceftazidime	PowderforInjection1000mg					87(E) dated 06.01.2023				12.88%
		30	Ceftazidime	Powder for Injection 250 mg					484(E) dated 02.02.2023				2.41%
		31	Ceftriaxone	PowderforInjection1000mg					87(E) dated 06.01.2023				7.05%
		32	Ceftriaxone	Powder for Injection 500 mg					87(E) dated 06.01.2023				10.33%
		33	Ceftriaxone	PowderforInjection2000mg					87(E) dated 06.01.2023				6.69%
		34	Ceftriaxone	Powder for Injection 250 mg					87(E) dated 06.01.2023				7.73%
		35	Cefuroxime	Tablet 500 mg					1578(E) dated 31.03.2023				53.28%
		36	Cefuroxime	Injection 1500 mg					1579(E) dated 31.03.2023				26.07%
		37	Cefuroxime	Oralliquid125mg/5mL(p)					5939(E) dated 19.12.2022				25.94%
		38	Ciprofloxacin	Tablet 500mg					87(E) dated 06.01.2023				3.82%
		39	Ciprofloxacin	Tablet 250mg					87(E) dated 06.01.2023				8.31%
		40	Ciprofloxacin	Oral liquid 250mg/5mL(p)					1577(E) dated 31.03.2023				5.70%
		41	Ciprofloxacin	Injection 200mg/100mL					194(E) dated 11.01.2023				4.17%
		42	Clarithromycin	Tablet500mg					5938(E) dated 19.12.2022				31.87%
		43	Clarithromycin	Tablet250mg					5938(E) dated 19.12.2022				27.08%
		44	Clarithromycin	Oralliquid125mg/5mL(p)					194(E) dated 11.01.2023				7.55%
		45	Clindamycin	Injection150mg/mL					1579(E) dated 31.03.2023				38.23%
		46	Co-trimoxazole [Sulphamethoxazole(A) +Trimethoprim(B)]*	Oral liquid 200 mg (A) + 40 mg(B)/5mL(p)					1577(E) dated 31.03.2023				3.57%
		47	Co-trimoxazole [Sulphamethoxazole(A) +Trimethoprim(B)]*	Tablet 400 mg (A) + 80 mg (B)					1577(E) dated 31.03.2023				4.75%
		48	Doxycycline	Power for Injection 100 mg					1579(E) dated 31.03.2023				32.29%
		49	Gentamicin	Injection40mg/mL (2ml)					2124(E) dated 04.05.2023				0.00%
		50	Gentamicin	Injection40mg/mL (1.5 ml)					2124(E) dated 04.05.2023				0.00%
		51	Gentamicin	Injection10mg/mL					879(E) dated 24.02.2023				33.99%
		52	Gentamicin	Injection40mg/mL (more than 20ml)					1577(E) dated 31.03.2023				0.00%
		53	Gentamicin	Injection40mg/mL (3ml-10ml)					1577(E) dated 31.03.2023				29.39%
		54	Gentamicin	Injection40mg/mL (11ml-20ml)					1577(E) dated 31.03.2023				4.80%
		55	Meropenem	Powderfor Injection1000mg (astrihydrate)					1579(E) dated 31.03.2023				66.37%
		56	Meropenem	Powder for Injection 500 mg (astrihydrate)					1579(E) dated 31.03.2023				71.15%

		57	Metronidazole	Tablet400mg					87(E) dated 06.01.2023				3.69%
		58	Metronidazole	Oralliquid200mg/5mL(p)					194(E) dated 11.01.2023				6.98%
		59	Metronidazole	Injection500mg/100mL					194(E) dated 11.01.2023				11.11%
		60	Metronidazole	Tablet200mg					87(E) dated 06.01.2023				3.08%
		61	Metronidazole SF	Injection500mg/100mL					486(E) dated 02.02.2023				11.11%
		62	Nitrofurantoin	Tablet 100 mg					87(E) dated 06.01.2023				9.97%
		63	Nitrofurantoin	Capsule 100 mg					1577(E) dated 31.03.2023				4.79%
		64	Nitrofurantoin	Oral liquid 25mg/5mL(p)					1577(E) dated 31.03.2023				9.97%
		65	Piperacillin (A) +Tazobactam(B)	PowderforInjection4000mg(A)+500mg(B)					87(E) dated 06.01.2023				26.52%
		66	Piperacillin (A) +Tazobactam(B)	PowderforInjection2000mg(A)+250mg(B)					87(E) dated 06.01.2023				20.27%
		67	Piperacillin (A) +Tazobactam(B)	PowderforInjection1000mg(A)+125mg(B)					87(E) dated 06.01.2023				9.41%
		68	Vancomycin	PowderforInjection1000mg					194(E) dated 11.01.2023				20.63%
		69	Vancomycin	Powder for Injection 500 mg					194(E) dated 11.01.2023				9.56%
		70	Vancomycin	Capsule 250mg					1577(E) dated 31.03.2023				12.52%
		71	Vancomycin	Powder for Injection 250 mg					194(E) dated 11.01.2023				7.37%
		72	Clindamycin	Capsule 150mg					5938(E) dated 19.12.2022				9.17%
		73	Clindamycin	Capsule 300mg					5938(E) dated 19.12.2022				3.59%
		74	Co-trimoxazole[Sulphamethoxazole(	Tablet 800mg (A) + 160mg (B)					4886 (E) dated 10.11.2023				1.67%
		75	Doxycycline	Capsule 100mg					484 (E) dated 02.02.2023				1.35%
		76	Doxycycline	Tablet 100mg					1577 (E) dated 31.03.2023				0.00%
									Average reduction				**12.42%**

Computation of Ceiling Price based on October, 2023 Data under DPCO, 2013															
						Number of Companies consisting of Market Share of 1% & Above									2
	4.2.10 &	Snake venom antiserum	As licensed	10ml Vial		Sum of MAT value considered for price calculation (in Lakhs)									2,134.67
	19.2.7	Lyophilized polyvalent	(P,S,T)			Sum of PTR per unit considered for price calculation									1720.39
						Number of Packs considered									3
						Average PTR									573.46
			Current Ceiling Price	**693.71**	**10ml Pack**	Add : 16% Retailer Margin									91.75
			Maximum Permissible PTR	**598.02**		Ceiling Price (without GST)									665.22
			(S.O. 1573(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)			% Reduction with compared to Highest Price									1.59%
						Final Ceiling Price (without GST)									665.22
											Minimum Price (Rs.)				554.97
											Maximum Price (Rs.)				582.71
											Average of all considered (Rs.)				573.46
											Ceiling Price (Rs.)				665.22
											Reduction from current ceiling price				4.11%
									TOTAL MAT	**21,55,33,872**	100%	M3			
S.No.	**Unique No. as per NLEM**	**Composition as per NLEM**	**पैक विवरण Pack Description**	**छापBRAND**	**कंपनी Company**	**Strength**	**Pack Size (Vial)**	**Unit**	**PTR(Rs.)**	**Brandwise MAT (Ignoring 0% MAT)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per Unit (Rs.)**	**Price per Unit (Rs.) Considered**
1	4.2.10 &	Snake venom	ANTI SNAKE INJECTION 10 ML	ANTI SNAKE	SERUM INSTITUTE OF INDIA LTD		1	Each Vial of 10ml	519.72	1050354	0.49%	0.49%	N	519.72	
2	19.2.7	antiserum- Lyophilized	ASVS LYOPHILIZED INJECTION 1(	ASVS	BHARAT SERUMS & VACCINES LTD		1	Each Vial of 10ml	582.71	95759240	44.43%	44.43%	Y	582.71	582.71
3		polyvalent	ASVS POLYVALENT INJECTION 1(	ASVS POLYVALE	SERUM INSTITUTE OF INDIA LTD		1	Each Vial of 10ml	582.71	93545622	43.40%	43.40%	Y	582.71	582.71
4			BENOM INJECTION 10 ML	BENOM	BIOLOGICAL E LTD		1	Each Vial of 10ml	469.2	1016757	0.47%	0.47%	N	469.20	
5			SNAKE VENOM ANTI SERUM WIT	SNAKE VENOM A	BHARAT SERUMS & VACCINES LTD		1	Each Vial of 10ml	554.97	24161900	11.21%	11.21%	Y	554.97	554.97